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ABSTRACT
Background: Both maternal and fetal complications are increased in diabetic 
pregnancies. Although hypertensive complications are increased in pregnant 
women with pregestational diabetes, reports on hypertensive complications in 
women with gestational diabetes mellitus (GDM) have been contradictory. 
Congenital malformations and macrosomia are the main fetal complications in 
Type 1 diabetic pregnancies, whereas fetal macrosomia and birth trauma but not 
congenital malformations are increased in GDM pregnancies. 
Aims: To study the frequency of hypertensive disorders in gestational diabetes 
mellitus. To evaluate the risk of macrosomia and brachial plexus injury (Erb’s 
palsy) and the ability of the 2-hour glucose tolerance test (OGTT) combined with 
the 24-hour glucose profile to distinguish between low and high risks of fetal 
macrosomia among women with GDM.  
To evaluate the relationship between glycemic control and the risk of fetal 
malformations in pregnancies complicated by Type 1 diabetes mellitus.  To assess 
the effect of glycemic control on the occurrence of preeclampsia and pregnancy-
induced hypertension in Type 1 diabetic pregnancies.    
Subjects: A total of 986 women with GDM and 203 women with borderline 
glucose intolerance (one abnormal value in the OGTT) with a singleton pregancy, 
488 pregnant women with Type 1 diabetes (691 pregnancies and 709 offspring), 
and 1154 pregnant non-diabetic women (1181 pregnancies and 1187 offspring) 
were investigated. 
Results: In a prospective study on 81 GDM patients the combined frequency of 
preeclampsia and PIH  was higher than in 327 non-diabetic controls (19.8% vs 
6.1%, p<0.001). On the other hand, in 203 women with only one abnormal value 
in the OGTT, the rate of hypertensive complications did not differ from that of the 
controls. Both GDM women and those with only one abnormal value in the 
OGTT had higher pre-pregnancy weights and BMIs than the controls. 
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In a retrospective study involving  385 insulin-treated and 520 diet-treated GDM 
patients, and 805 non-diabetic control pregnant women, fetal macrosomia 
occurred more often in the insulin-treated GDM pregnancies (18.2%, p<0.001) 
than in the diet-treated GDM pregnancies (4.4%), or the control pregnancies 
(2.2%). The rate of Erb’s palsy in vaginally delivered infants was 2.7% in the 
insulin-treated group of women and 2.4% in the diet-treated women compared 
with 0.3% in the controls (p<0.001). The cesarean section rate was more than 
twice as high (42.3% vs 18.6%) in the insulin-treated GDM patients as  in the 
controls.  
 
A major fetal malformation was observed in 30 (4.2%) of the 709 newborn infants 
in Type 1 diabetic pregnancies and in 10 (1.4%) of the 735 controls (RR 3.1, 95% 
CI 1.6–6.2). Even women whose levels of HbA1c (normal values less than 5.6%) 
were only slightly increased in early pregnancy (between 5.6 and 6.8%) had a 
relative risk of fetal malformation of 3.0 (95% CI 1.2–7.5). Only diabetic patients 
with a normal HbA1c level (<5.6%) in early pregnancy had the same low risk of 
fetal malformations as the controls.  
 
Preeclampsia was diagnosed in 12.8% and PIH in 11.4% of the 616 Type 1 
diabetic women without diabetic nephropathy. The corresponding frequencies 
among the 854 control women were 2.7%  (OR 5.2; 95% CI 3.3–8.4) for 
preeclampsia and 5.6% (OR 2.2, 95% CI 1.5–3.1) for PIH. Multiple logistic 
regression analysis indicated that glycemic control, nulliparity, diabetic 
retinopathy and duration of diabetes were statistically significant independent 
predictors of preeclampsia. The adjusted odds ratios for preeclampsia were 1.6 
(95% CI 1.3–2.0) for each 1%-unit increment in the HbA1c value during the first 
trimester and 0.6 (95% CI 0.5–0.8) for each 1%-unit decrement during the first 
half of pregnancy. In contrast, changes in glycemic control during the second half 
of pregnancy did not alter the risk of preeclampsia. 
 
Conclusions: In type 1 diabetic pregnancies it is extremely important to achieve 
optimal glycemic control  before pregnancy and maintain it throughout pregnancy 
in order to decrease the complication rates both in the mother and in her offspring. 
The rate of fetal macrosomia  and birth trauma in GDM pregnancies, especially in 
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the group of insulin-treated women, is still relatively high. New strategies for 
screening, diagnosing, and treatment of GDM must be developed in order to 






Diabetes mellitus complicates 3–5% of pregnancies increasing the risk of both 
maternal and perinatal morbidity and mortality (Gabbe and Graves 2003).  
 
Gestational diabetes mellitus (GDM) is defined as glucose intolerance of variable 
severity with onset or first recognition during pregnancy (Metzger and Coustan 
1998). It complicates 2–5% of all pregnancies (Gabbe and Graves 2003). Obesity 
is an increasing problem worldwide (Catalano 2007a) and overweight women are 
especially at risk of developing GDM (Callaway et al. 2006, Chu et al. 2007). 
Fetal macrosomia is the most important perinatal complication in women with 
GDM (Gabbe and Graves 2003). The incidence of trauma among mothers and 
their offspring is  increased in cases of vaginal delivery after pregnancies 
complicated by GDM (Langer et al. 2005b). The incidence of cesarean section 
delivery is also increased in GDM pregnancies (Sermer et al. 1998). Gestational 
diabetes mellitus may precede Type 2 diabetes mellitus later in life (Ben-Haroush 
et al. 2004).
 
Type 2 diabetes mellitus, which  is characterized by insulin resistance and relative 
insulin deficiency (Maedler 2008), occurs later in life and is often associated with 
obesity.The incidence of Type 2 diabetes mellitus has increased during the last 
two decades worldwide. This is also reflected in  an increase in Type 2 diabetic 
pregnancies (Feig and Palda 2002, Dunne 2005). The incidence of obstetric and 
perinatal complications in Type 2 diabetic pregnancies equals or is even higher 
than that associated with Type 1 diabetic pregnancies (Macintosh et al. 2006, Bell 
et al. 2008). 
 
Type 1 diabetes mellitus is an autoimmune condition, in which the beta cells of 
the pancreas are destroyed eventually necessitating insulin replacement therapy 
(Taplin and Barker 2008). It  generally occurs early in life and complicates 0.2–
0.4% of pregnancies (Engelgau et al. 1995, von Kries et al. 1997). In Finland the 
incidence of Type 1 diabetes is the highest in the world and in Finnish children it 
is increasing even faster than before (Tuomilehto et al. 1999, Harjutsalo et al. 
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2008). It has been estimated that 0.6% of childbirths are complicated by Type 1 
diabetes in Finland.  
 
Major fetal malformations are often associated with poor glycemic control before 
or during early pregnancy (Mills et al. 1979, Kitzmiller et al. 1996). Fetal 
malformations represent one of the main causes of increased perinatal mortality 
among pregnant women with pregestational diabetes (Gabbe and Graves 2003). 
The prevalence of major congenital malformations in Type 1 and Type 2 diabetic 
pregnancies is  2–4 times higher than in the general population (Macintosh et al. 
2006, Yang et al. 2006).  
 
Fetal macrosomia is one of the main perinatal complications in all types of 
diabetic pregnancy,  especially in women  with poor glycemic control  (Gabbe and 
Graves 2003). It has been suggested that all infants of women with Type 1 
diabetes are actually macrosomic (Bradley et al. 1988). Fetal macrosomia 
increases the risk of birth trauma, particular brachial plexus nerve injury (Erb’s 
palsy) (Christoffersson and Rydhstroem 2002). Fetal hypoxia (Teramo et al. 2004) 
and neonatal asphyxia (Barnes-Powell 2007) are also increased in Type 1 diabetic 
pregnancies. The risk of preeclampsia  is increased in women with Type 1 
diabetes (Sibai 2000), especially those with diabetic nephropathy (Howarth et al. 
2007). Diabetic nephropathy also increases the risk of fetal growth restriction 
(Reece et al. 1998). 
 
In the present studies the effect of glycemic control on the occurrence of 
preeclampsia and pregnancy-induced hypertension (PIH) in GDM or Type 1 
diabetic pregnancies was assessed. The relationship between glycemic control and 
the risk of fetal malformations in pregnancies complicated by Type 1 diabetes 
mellitus was also evaluated. Finally, a method was developed for detecting 
women with GDM at a high risk of delivering a macrosomic infant.   
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REVIEW OF THE LITERATURE 
1. Glucose metabolism and pregnancy 
1.1 Normal pregnancy 
Maternal glucose metabolism changes throughout pregnancy. Concentrations of 
fasting blood glucose decreases as early as in the first trimester and remain low 
throughout pregnancy compared with fasting levels before pregnancy (Pedersen 
1977a, Mills et al. 1998). In contrast, postprandial glucose values increase from 
the 16th pregnancy week until the 36th pregnancy week (Siegmund et al. 2008). 
During the first half of pregnancy, basal insulin levels are normal or slightly 
elevated, coinciding with a decrease of about 10% in fasting blood glucose values 
(Kühl 1975, Freinkel 1985, Hollingsworth 1985). Basal insulin levels increase by 
50–80% in the third trimester (Kühl 1975). Normally the development of 
increasing insulin resistance during pregnancy is compensated for by a 
simultaneous increase in insulin secretion (Ryan et al. 1985, Buchanan et al. 1990, 
Sivan et al. 1997). Mild glucosuria in normoglycemic mothers is considered 
physiological, because glucose reabsorption from the renal tubules is decreased 
during pregnancy (Davison and Dunlop 1980). 
 
 
Placental glucose transfer from mother to fetus takes place by facilitated diffusion 
(Leonce et al. 2006). The transport mechanism is controlled by blood glucose 
concentrations both in the fetus and in the mother. The primary transporter 
responsible for maternal-to-fetal glucose transport, placental glucose transporter 1 
(GLUT1), was first described by Fukumoto et al. (1988) and Bell et al. (1990). 
Insulin-like growth factors IGF-1 and IGF-2 also stimulate glucose transport 
across the placenta (Kniss et al. 1994). 
 
 
Fetal blood glucose levels are lower than  maternal levels, but they correlate 
linearly (Raivio and Teramo 1968, Hay and Sparks 1985). Fetal insulin 
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production  starts during the first trimester (Adesanya et al. 1966), but it responds 
to increased glucose levels only during the latter half of pregnancy (Adam et al. 
1969). Free insulin does not cross the placenta (Adam et al. 1969).  
 
1.2 Gestational diabetes mellitus 
 
Impaired insulin secretion may vary from complete failure (such as in Type 1 
diabetes) to a partial defect occurring only under circumstances of  increased need 
such as pregnancy (GDM) or obesity (Type 2 diabetes). The basic metabolic 
defect in women with GDM is the limited capacity of pancreatic beta cells to 
increase their insulin secretion to compensate for the progressively increasing 
insulin resistance during pregnancy (Buchanan et al. 1990, Catalano et al. 1993, 
Xiang et al. 1999). Postprandial hyperglycemia is common in women with GDM 
(Buchanan et al. 1990). Because postprandial glucose levels are dependent on the 
carbohydrate and fat content of the meal, the main treatment in GDM pregnancies 
is dietary intervention.  
 
 
Gestational diabetes mellitus is defined as any degree of glucose intolerance with 
the onset or first recognition during pregnancy. The diagnosis is based on an oral 
glucose tolerance test (OGTT)  done with a 75 g glucose load. Diagnostic criteria 
for the 75-g OGTT are for fasting plasma glucose 5.3, for the 1-hour value 10.0 
and for the 2-hour value 8.6 mmol/l (Metzger and Coustan 1998, The Finnish 
Working Group on Gestational Diabetes 2008). Until 2008 the following criteria 
were used in Finland to diagnose GDM according to the 2-hour OGTT: two or 
more glucose values above: fasting 5.1, 1-hour 10.00 and 2-hour 8.7 mmol/l 
(venous plasma or capillary whole blood). The cut-off values were for venous 




The prevalence of GDM differs considerably in different ethnic populations. In 
the United States the prevalence of GDM ranges from 1 to 14%, with 2–5% being 
the most common rate (Ben-Haroush et al. 2008). The adjusted relative risk of 
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GDM in black women has been reported to be 1.81 (95% CI 1.13–2.89) and in 
Hispanic women 2.45 (95% CI 1.48–4.04) compared with Caucasian women 
(Dooley et al. 1991). In another study, in Australia Asian women were more likely 
to have GDM than Caucasian women (Gunton et al. 2001). 
 
Obesity among pregnant women is increasing worldwide (Catalano 2007a).  This 
is also true in Finnish women with GDM, Type 1 or Type 2 diabetes (Teramo, 
unpublished observations). Elevated BMI is clearly associated with an increased 
risk of GDM (Bottalico 2007). Chu et al. (2007) reported, in a meta-analysis 
including twenty studies, that unadjusted ORs of GDM were 2.14 (95% CI 1.82–
2.53), 3.56 (95% CI 3.05–4.21), and 8.56 (95% CI 5.07–16.04) among overweight 
(BMI 25–29.9 kg/m2), obese (30–40 kg/m2) and severely obese (>40 kg/m2) 
pregnant women compared with normal-weight (BMI <25.0 kg/m2) pregnant 
women, respectively. Callaway et al. (2006) showed that overweight (BMI 25.01–
30 kg/m2), obese (30.01–40 kg/m2) and morbidly obese women (>40 kg/m2) were 
at increased risk of GDM, with ORs of 1.78 (95% CI 1.25–2.52), 2.95 (95% CI 
2.05–4.25) and 7.44 (95% CI 4.42–12.54), respectively. Also,  excessive weight 
gain during pregnancy can lead to an increased risk of GDM (Kabiru and Raynor 
2004). Furthermore, Villamor and Cnattingius (2006) showed that when pre-
pregnancy BMI increased from the first to the second pregnancy, the occurrence 
of GDM also increased in the subsequent pregnancy. Women who gained 3 or 
more units of BMI by their next pregnancy had an adjusted OR for GDM  of 2.09 
(95% CI 1.68–2.61). The association between the risk of  GDM and weight gain 
was linear, and was also noted in women with normal pre-pregnancy BMI, which 
suggests that even a modest increase in BMI could result in perinatal 
complications. In a Swedish study, Zetterström et al. (2005) found that chronic 




The main goal of treatment in GDM pregnancies is to achieve normoglycemia, i.e. 
to prevent both fasting and postprandial hyperglycemia from the diagnosis of 
GDM until labor and delivery. When women with GDM achieve normoglycemia, 
their weight gain during pregnancy is usually less than that of healthy pregnant 
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women (Suhonen and Teramo 1993). If normoglycemia cannot be maintained by 
diet alone, insulin therapy is started. Recently, it has been reported that treatment 
with glyburide alone (Langer et al. 2000, 2005a) or with metformin alone or with 
supplemental insulin (Rowan et al. 2008) is an effective and safe treatment option 
for women with GDM. Immediately after delivery, women with GDM rarely need 
to continue with insulin or oral medication treatment in order to maintain 
euglycemia. However, they remain at an increased risk of Type 2 diabetes 
mellitus later in life and they should therefore have regular check-ups for blood 
glucose levels for the rest of their lives. 
1.3 Type 1 diabetes mellitus 
In Type 1 diabetes mellitus, insulin secretion is either totally lacking or severely 
impaired. During pregnancy in Type 1 diabetics, the requirement of insulin to 
maintain the same glycemic level increases from the end of the first trimester until 
the end of pregnancy. On average, the insulin need increases from 0.7 IU/kg body 
weight per day in the first trimester to 0.8 IU/kg per day in the second trimester 
and to 0.9 IU/kg per day in the third trimester until 36 weeks of pregnancy. At 
term the insulin requirement is 1.0 IU/kg per day (Jovanovic and Kitzmiller 
2008). However, individual variation in the increase of insulin requirement during 
pregnancy is relatively large. During the first weeks of pregnancy, insulin 
sensitivity is often increased, which at least partly explains the increase in 
hypoglycemic episodes in Type 1 diabetic mothers during the first trimester 
(Nielsen et al. 2008). Gabbe and Graves (2003) reported that insulin requirements 
increase throughout pregnancy, most markedly in the period between 28 and 32 
weeks of gestation, after which it can actually decrease in some Type 1 diabetic 
mothers. After parturition, the daily insulin requirement decreases within a day or 
two to the pre-pregnancy level (Buchanan et al. 1985, Jovanovic and Kitzmiller 




1.4 Monitoring glycemic control  
 
Optimal glycemic control during diabetic pregnancy is the basis for good 
outcome, both for the mother and her newborn infant (Pedersen 1977d, Langer et 
al. 1989, Inkster et al. 2006). Monitoring of both preprandial and postprandial 
blood glucose values is important in order to achieve euglycemia  (Crowther et al. 
2005, Fadl et al. 2006, Jovanovic 2008, Kitzmiller et al. 2008). Recently, 
subcutaneous continuous glucose monitoring has increasingly been used to 
achieve maternal normoglycemia in order to reduce the risk of fetal macrosomia 
and neonatal hypoglycemia in diabetic pregnancies (Kerssen et al. 2007, Kestilä et 
al. 2007, Stenninger et al. 2008).
Monitoring glycemic control has been greatly improved by the introduction of 
methods which reflect the mean blood glucose level over a prolonged period of 
time. The chemical reaction between glucose and proteins results in production of 
nonenzymatically glycated proteins in blood and tissues. The level of glycation of 
hemoglobins is proportional to the average glucose concentration during the 
previous 4 to 8 weeks (Bunn et al. 1978) and therefore it does not detect rapid 
changes in plasma glucose concentration. The glycation level also depends  on the 
lifespan of red blood cells in the circulation. The turnover rate of red blood cells 
during pregnancy is about 90 days, compared with 120 days in non-pregnant 
adults (Albertson and Jovanovic 2008). The amount of glycated hemoglobin is 
expressed as a percentage of the total hemoglobin.  
 
 
Early methods for fractionation of hemoglobin included cation exchange column 
chromatography. The procedures were elaborate and time-consuming, requiring 
several days of work. Subsequently, automated methods, such as high-
performance liquid chromatography (HPLC), were developed (Dunn et al. 1979, 
Gruber and Koets 1979). Stenman et al. (1984) developed a fully automated rapid 
HPLC method for the measurement of hemoglobin A1c (HbA1c) levels. The 
method permits separation and quantification of HbA1c, even in the presence of 
elevated levels of fetal hemoglobin (HbF). It has been shown recently that a 1% 
unit increase in the HbA1c level equals a mean plasma glucose increase of  1.6 
mmol/l in non-pregnant diabetic adults (Nathan et al. 2008).  
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Several recommendations exist for evaluating glycemic control in women with 
GDM. A relatively recent recommendation is that both pre- and postprandial 
glucose levels should be measured four times a day (Gabbe and Graves 2003). 
The optimal time for measuring the postprandial glucose level is one hour after 
the meal (Bühling et al. 2005). Insulin- treated women with GDM should measure 
their blood glucose level 5-6 times each day (Jovanovic 2008). Subcutaneous 
continuous glucose monitoring is a new method for measuring glucose values 
continuously over several days. However, its advantage over self-monitoring of 




2. Maternal outcome  
 
2.1 Maternal hypoglycemia  
 
Maternal hypoglycemia is a well-recognized and potentially dangerous 
complication of intensive insulin therapy in pregnant women with Type 1 
diabetes.  Severe hypoglycemia is defined as impairment of consciousness of a 
diabetic, who needs help from another person to administer glucose orally or to 
give a glucagon injection or intravenous glucose infusion (ADA workgroup 
2005). Severe hypoglycemia during pregnancy occurs in 41–45% of Type 1 
diabetic women (Evers et al. 2002a, Nielsen et al. 2008) The risk of severe 
hypoglycemia is greatest during the first trimester of pregnancy (Rosenn et al. 
1995, Evers et al. 2002a, Nielsen et al. 2008). Subjective symptoms of low blood 
glucose levels are often diminished during pregnancy, which decreases the 
patient’s awareness of hypoglycemia (Björklund et al. 1998, Nielsen et al. 2008). 
Furthermore, pregnancy attenuates glucose counter-regulation mechanisms during 
hypoglycemia in Type 1 diabetic women (Diamond et al. 1992, Rosenn et al. 
1996). Therefore, intensive insulin therapy during pregnancy predisposes patients 
to severe hypoglycemia in cases of Type 1 diabetes. Recurrent severe maternal 
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hypoglycemic episodes during pregnancy can result in impairment of cognitive 
functions of the mother (Langan et al. 1991, Deary and Frier 1996).  
 
Animal studies indicate that maternal hypoglycemia is teratogenic during 
organogenesis (Buchanan et al. 1986, Smoak and Sadler 1990, ter Braak et al. 
2002). However, studies in pregnant women with Type 1 diabetes have not 
revealed  any association between maternal hypoglycemia and adverse fetal 
outcome (Rosenn and Miodovnik 2000) or diabetic embryopathy (Mills et al. 
1988, Steel et al. 1990, Kitzmiller et al. 1991, ter Braak et al. 2002). Similarly, no 
abnormal changes in fetal behavior have been reported in women with Type 1 
diabetes during induced moderate maternal hypoglycemia (Diamond et al. 1992, 
Rosenn et al. 1996). 
 
 
2.2 Preeclampsia and pregnancy-induced hypertension
 
Preeclampsia is defined as hypertension with a diastolic blood pressure repeatedly 
above 90 mmHg during the second half of pregnancy, in combination with 
proteinuria (Cunningham and Lindheimer 1992, Roberts and Redman 1993). 
However, the definition of preeclampsia varies in different publications (Harlow 
and Brown 2001). Pregnancy-induced hypertension (PIH) is defined as high blood 
pressure (diastolic blood pressure repeatedly over 90 mmHg) during the second 
half of pregnancy without proteinuria. 
 
Preeclampsia is a disease of unknown etiology (Redman and Sargent 2005). 
However, it is characterized by widespread endothelial cell dysfunction (Roberts 
et al. 1989, 1991, Rodie et al. 2004, Sibai et al. 2005). Moreover, preeclampsia is 
also characterized by insulin resistance, immune maladaption, coagulation defects 
and increased systemic inflammatory response (Kaaja et al. 1999, Rodie et al. 




Preeclampsia complicates about 4% of pregnancies in nulliparous women and 
about 2% in multiparous women (Sibai et al. 2005), and it is one of the major 
pregnancy complications causing increased morbidity and mortality in both the 
mother and the newborn infant (Roberts and Cooper 2001). Preeclampsia and PIH 
increase the risk of iatrogenic preterm birth and intrauterine growth restriction and 
these women are at an increased risk to obtain cardiovascular disease later in life 
(Rodie et al. 2004, Sibai et al. 2005). In a Swedish study 5.2% of 10 666 pregnant 
women developed preeclampsia, and 4.4% developed PIH (Ros et al. 1998). In 
another Swedish study, Östlund et al. (2004) analyzed 430 852 singleton 
deliveries using the Swedish Medical Birth Registry and found that the incidence 
of preeclampsia was 2.8% in non-diabetic women. Eclampsia (maternal seizures) 
is a rare complication of pregnancy in the developed world. In Finland, the 
incidence of eclampsia was 2.4 per 10 000 births in the 1990s (Ekholm et al. 
1999). Similarly, in a Swedish study the incidence of eclampsia was 3.3 (Kullberg 
et al. 2002) and in a study in the UK, 2.7 per 10 000 births (Knight 2007). 
 
 
Nulliparity is associated with a 2.4- to 2.6-fold elevated risk of  preeclampsia 
(Funai et al. 2005, Luo et al. 2007). Advanced  maternal age and multiple 
pregnancies also increase the risk (Coonrod et al. 1995, Funai et al. 2005). 
Women with previous severe preeclampsia have a high risk of preeclampsia in 
subsequent pregnancies (Sibai et al. 1986, 1991). A family history of 
preeclampsia is associated with a three- to four-fold increased risk of 
preeclampsia (Cincotta and Brennecke 1998). 
 
  
2.2.1 Impact of obesity 
 
Obesity may be the most common cause of insulin resistance. Insulin secretion is 
three to four times higher in obese subjects than in lean controls (Polonsky et al. 
1996). Obesity is a risk factor as regards developing preeclampsia as well as PIH 
(Sibai et al. 1995, Jensen et al. 2003a). Ros et al. (1998) compared underweight 
women (BMI <19.8 kg/m2) with obese women (BMI >29 kg/m2). The obese 
women had increased risks of both preeclampsia (OR 5.19, 95% CI 2.35–11.48) 
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and PIH (OR 4.85, 95% CI 1.97–11.92). Even in normal pregnancy, insulin 
resistance increases, but this change is exaggerated in women with preeclampsia 
(Rodie et al. 2004). In a recent study, the risks of preeclampsia and PIH were 1.9- 
and 1.5-fold higher, respectively, in overweight women (prepregnancy BMI 26.1–
29 kg/m2) than in normal weight women (BMI 19.8–26 kg/m2) (Belogolovkin et 
al. 2007).  
 
Weight gain during pregnancy has gradually increased in the United States during 
the last 15–20 years (Catalano 2007b). Excessive maternal weight gain during 
pregnancy increases the rates of adverse obstetric and neonatal outcomes. 
DeVader et al. (2007) reported that in pregnancies with a weight gain over 15.9 
kg, preeclampsia occurred more frequently (OR 1.88, 95% CI 1.74–2.04) than in 
pregnancies with a recommended weight gain of 11.4–15.9 kg. On the other hand, 
preeclampsia occurred more seldom (OR 0.56, 95% 0.49–0.64) when the weight 
gain was under 11.4 kg. Similarly, Kiel et al. (2007), using the same birth registry, 
reported that the risk of preeclampsia was significantly lower when the weight 
gain in overweight and obese women was less than 6.8 kg. In the study by 
Villamor and Cnattingius (2006) an increase in pre-pregnancy BMI of at least 3 
units from the first to the second pregnancy was associated with increased 
frequencies of both preeclampsia (OR 1.78, 95% CI 1.52–9.08) and PIH (1.76, 
95% CI 1.18–2.61). In another Swedish study Zetterström et al. (2005) reported 
that chronic hypertensive disease is an independent risk factor of preeclampsia 
(OR 3.8, 95% CI 3.4–4.3). 
 
2.2.2 Gestational diabetes mellitus 
 
Reports on the relationship between GDM and preeclampsia have been 
contradictory. Jacobson and Cousins (1989) and Schaffir et al. (1995) found no 
relationship between GDM and pregnancy-induced hypertensive disorders. 
However,  Nordlander et al. (1989) and Hunger-Dathe et al. (2005) reported that 
women with GDM more frequently had preeclampsia than healthy controls. The 
incidence of preeclampsia in women with GDM has been reported to range from 
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6.1% to 14.4% (Starcevic and Djelmis 2004, Yogev et al. 2004b, Östlund et al. 
2004 , Hunger-Dathe et al. 2005). Even minor degrees of glucose intolerance are 
associated with an increased incidence of preeclampsia (Sermer et al. 1995, Khan 
and Daya 1996). Lindsay et al. (1989) found that the incidence of preeclampsia 
was 7.9% in women with one abnormal value in the OGTT, compared with 3.3% 
in healthy controls. Ros et al. (1998) showed that GDM was significantly 
associated with an increased risk of preeclampsia (OR 3.11, 95% CI 1.61–6.00). 
In the study of Östlund et al. (2004) the adjusted OR for GDM as a risk factor of 
preeclampsia was 1.61 (95% CI 1.39–1.86).  
 
Barden et al. (2004) reported that insulin resistance in women with GDM 
precedes the development of preeclampsia. Yogev et al. (2004a) found that GDM 
women who developed preeclampsia had significantly higher systolic and 
diastolic blood pressure values throughout the first and second trimester of 
pregnancy compared with GDM women without preeclampsia. In another study, 
Yogev et al. (2004b) reported that the rate of preeclampsia was influenced by the 
severity of GDM, and improved glycemic control during pregnancy decreased the 
rate of preeclampsia. Similarly, in the study of Starcevic and Djelmis (2004) 
preeclampsia frequency increased with increasing blood glucose values. However, 




2.2.3 Type 1 diabetes mellitus 
 
It has long been known that Type 1 diabetes mellitus considerably increases  the 
risk of preeclampsia  (White 1949, Kyle 1963, Pedersen et al. 1974, Reece 1998). 
In the study of Ros et al. (1998) Type 1 diabetes was associated with an increased 
risk of preeclampsia (OR 5.58, 95% CI 2.72–11.43. Furthermore, Type 1 diabetic 
women with vascular complications are more likely to develop preeclampsia (OR 
3.5, 95% CI 1.28–9.53) than women without vascular complications (Howarth et 
al. 2007).  Sibai et al. (2000) reported  an overall incidence of preeclampsia of 
20% in Type 1 diabetic women. The frequency of preeclampsia rose significantly 
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with increasing severity of diabetes according to White’s classification (in classes 
R-F it was 36%). The risk of preeclampsia is over 50% in women with diabetic 
nephropathy (White 1949, Kitzmiller et al. 1981, Ekbom et al. 2001).  Even 
microalbuminuria in early pregnancy in women with Type 1 diabetes increases 
the risk of  preeclampsia more than in uncomplicated Type 1 diabetic pregnancies 
(Combs et al. 1993, Ekbom et al. 2000, 2001). 
 
Gordin et al. (2007) showed that preeclampsia but not PIH in women with type 1 
diabetes may be a risk factor for diabetic nephropathy later in life. However,it has 
also been reported that Type 1 diabetes mellitus is associated with an increased 
incidence of PIH (Garner et al. 1990, Siddiqi et al. 1991). 
 
The results of several studies suggest an association between poor glycemic 
control in early pregnancy in women with Type 1 diabetes, and preeclampsia 
(Combs et al. 1993, Rosenn et al. 1993, Hsu et al. 1996, 1998, Hanson and 
Persson 1998). Hsu et al. (1996) reported that an improvement of glucose control 
during pregnancy reduced the risk of preeclampsia. Similarly, Temple et al. 
(2006) reported that HbA1c levels were higher at 24 weeks of pregnancy in Type 1 
diabetic women with preeclampsia than in women without preeclampsia.  
 
2.3 Cesarean section  
 
Women with GDM (Sermer et al. 1998, Langer et al. 2005b) and Type 1 diabetes  
(El-Sayed and Lyell 2001) have an increased risk of cesarean section delivery. 
The majority of diabetic women with vascular complications  are delivered by 
cesarean section. 
 
Fetuses of diabetic women are frequently macrosomic (Bradley et al. 1988, 
Schwartz and Teramo 2000), which increases the rate of cesarean section 
deliveries. In a study by Jolly et al. (2003), macrosomia, defined as birth-weight 
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over the 90th percentile, was more likely in women with pregestational diabetes 
(OR 6.97, 95% CI 5.36–8.16) and GDM (OR 2.77, 95% CI 2.51–3.07) and this 
increased the risk of emergency cesarean sections (OR 1.84, 95% CI 1.75–1.93). 
Steer (2004) reported that women with GDM and overt diabetes had a greater 
likelihood of delivering an infant weighing over 4000 g than women with normal 
glucose tolerance and that macrosomic fetuses were more than twice as likely to 
be delivered by emergency cesarean section as fetuses weighing less than 4000 g. 
The increased risk of maternal complications in diabetic women seems at least 




Although fetal macrosomia is the leading reason for cesarean delivery in diabetic 
women, chronic fetal hypoxia, particularly in women with poor glycemic control 
during the last weeks of pregnancy, also increases the risk of cesarean delivery 
(Teramo et al. 2004). 
2.4 Maternal childbirth trauma    
Delivery of a macrosomic infant increases the risk of both maternal and neonatal  
injury. In a study by Stotland et al. (2004), diabetes was associated  with  
macrosomia, fourth-degree perineal lacerations and postpartum hemorrhage. Both 
forceps and vacuum extraction deliveries are additional risk factors for trauma. In 
a study by Johnson et al. (2004) forceps delivery was associated with an increase 
in major perineal and vaginal tears  (OR 1.85, 95% CI 1.27–2.69). Jolly et al. 
(2003) analyzed data from 350 311 singleton pregnancies between 1988 and 1997 
using logistic regression analysis and found that macrosomia, defined as birth-
weight over 4000 g, predicted  increased risks of both third degree perineal 
lacerations (OR 2.73; 95% CI 2.30–3.23) and postpartum hemorrhage (OR 2.10; 
95% CI 1.93–2.10).
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2.5. Maternal mortality     
 
Maternal mortality is defined by the World Health Organization (WHO) as 
pregnancy-related (accidents excluded) death rate per 100 000 during pregnancy 
or within 42 days after delivery. In a review including the English literature from 
1975 to 2001 and covering  publications evaluating maternal mortality in relation 
to the mode of delivery, Vadnais and Sachs (2006) reported that the overall 
maternal mortality rate ranged from 6 to 54 deaths per 100 000 live births. 
Operative delivery clearly is associated with an increased risk of maternal 
mortality. Cesarean section for any reason is associated with a 3–13 times 
increased risk compared with vaginal delivery. In a study carried out in the 
Netherlands and covering 1983 to 1992, the risk of dying in connection with 
cesarean delivery was 13 per 100 000 operations (Schuitemaker et al. 1997), 
which was 3 times the risk of maternal mortality after vaginal delivery. 
 
The incidence of maternal mortality in women with Type 1 diabetes is about 0.5% 
(Gabbe et al. 1976, Cousins 1987). Leinonen et al. (2001) reported the same 
maternal mortality rate  (0.51%, or 5/972) among consecutive Type 1 diabetic 
mothers with childbirth at the University Central Hospital of Helsinki between 
1975 and 1997. It was 109 times greater than that in the general population, but 
only 3.4 times greater than that in non-pregnant women with Type 1 diabetes of 
the same age in Finland (Lounamaa 1993). Severe hypoglycemia, massive 
bleeding, anesthetic complications and high maternal age are important 
contributing factors to maternal deaths in Type 1 diabetic pregnancies 
(Schuitemaker et al. 1997, Leinonen et al. 2001).  
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The incidence of congenital malformations is two to six times higher in 
pregnancies of women with Type 1 diabetes mellitus than in healthy women 
(Garner 1995, Kitzmiller et al. 1996, Platt et al. 2002, Vääräsmäki et al. 2002, 
Macintosh et al. 2006, Yang et al. 2006). The most common congenital 
malformations among women with Type 1 diabetes are cardiac, skeletal, CNS, 
uro-genital, gastro-intestinal, and facial malformations (Merlob 2008).  
 
The majority of the studies have demonstrated a relationship between maternal 
hyperglycemia in early pregnancy and the occurrence of malformations (Miller et 
al. 1981, Ylinen et al. 1984, Rose et al. 1988, Greene et al. 1989, Nielsen et al. 
2006). Preconception counseling, pregnancy planning and improvement of 
glycemic control before conception are associated with a decrease in the rate of 
malformations (Fuhrmann et al. 1983, Mills et al. 1988, Steel et al. 1990, 
Kitzmiller et al. 1991, McElvy et al. 2000, Evers et al. 2004, Inkster et al. 2006, 
Pearson et al. 2007). Most fetal malformations start to develop already before the 
7th week of pregnancy (Mills et al. 1979). Therefore, it is of utmost importance to 
achieve and maintain euglycemia already before pregnancy. 
 
 
Although a strong association exists between hyperglycemia and malformations, 
the exact mechanism or mechanisms responsible for abnormal fetal development 
have not been completely elucidated. Experimental studies suggest that oxidative 
stress may have an important role in the teratogenicity of diabetic pregnancies 
(Cederberg and Eriksson 2005). Eriksson and coworkers have shown that folic 
acid supplementation alone or in combination with vitamin E decreases the rate of 
malformation in the embryos of  diabetic rats (Wentzel et al. 2005, Gäreskog et al. 
2006).  
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The prevalence of congenital malformations among the offspring of mothers with 
gestational diabetes mellitus is similar to or only slightly higher than that in the 
general non-diabetic obstetric population (Janssen et al. 1996, Aberg et al. 2001). 
It has been suggested that a subgroup with an increased risk of malformations 
exists among women with GDM, perhaps as a result of pregestational but 




3.2 Fetal growth 
3.2.1 Normal growth 
 
Fetal growth is primarily controlled by the capability of the placenta to transport 
nutrients and oxygen to the fetus (Carrera and Devesa 1998). Normal fetal growth 
is  proportional and linear (Elejalde and de Elejalde 1986). Catecholamines, 
angiotensin II, aldosterone and prostaglandins play important roles in maintaining 
uteroplacental blood flow and are indirectly involved in fetal growth by ensuring 
adequate concentrations of oxygen, glucose and nutrients to the fetus (Carrera et 
al. 1998). Human chorionic somatomammotropin is an important placental 
hormone related to fetal growth (Carrera et al. 1998, Jovanovic and Kitzmiller 
2008). Only 10% of the fetal weight at term is reached during the first half of 
pregnancy and 2/3 is acquired during the last trimester. Fetal weight gain occurs 
mainly in the third trimester when fetal insulin acts as a strong growth-promoting 
hormone (Hill 1976). Locally produced peptide growth factors coordinate fetal 
growth (Hill et al. 1998). The insulin-like growth factors IGF-1 and IGF-2 in 
particular play an important regulatory roles in fetal growth (Forbes and 
Westwood 2008). In addition, fibroblast growth factor-2 (FGF-2) has been shown 
to be involved in the regulation of fetal growth (Hill et al. 1998). Maternal and 
fetal serum levels of FGF-2 both correlate directly with fetal and placental size 
(Hill et al. 1995). 
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Maternal pre-pregnancy weight has a strong association with fetal size (Love and 
Kinch 1965, Griffiths et al. 2007), whereas maternal height is only weakly 
associated with birth weight (Kirchengast et al. 1998, Griffiths et al. 2007). The 
quality of the diet and the maternal  ability to nourish the fetus properly are 
important factors affecting fetal growth (Carrera et al. 1998). Fetal genotype 
accounts for about 15% of the variation in birth weight (Carrera et al. 1998).  
 
3.2.2 Fetal macrosomia 
Definition  
Fetal macrosomia is defined in many different ways in the literature, e.g. as an 
absolute birth-weight, over 4000 g or over 4500 g, or as a relative birth-weight, 
either above the 90th percentile or above  +2 SD of the mean (97.7th percentile) of 
a standard population. Absolute birth weights are used when gestational ages are 
not known. Relative birth weights are preferable when the duration of pregnancy 
and fetal sex are known.  
 
Prevalence  
Fetal macrosomia complicates 30–50% of pregnancies in women with 
pregestational diabetes (Teramo 1998, Evers et al. 2004, Yang et al. 2006). It has 
been suggested that all fetuses of Type 1 diabetic mothers are actually 
‘macrosomic’ (Bradley et al. 1988). These investigators observed that the birth-
weight distribution of 280 consecutive offspring of Type 1 diabetic women was 
normally distributed, with the mean shifted to the right by 1.23 SDs compared 
with a standard population.  There was a similar observation  among 599 
consecutive offspring of Type 1 diabetic women at Helsinki University Central 
Hospital (Teramo 1998).  
 
Etiology  
Both maternal diabetes and BMI are independently related to fetal growth 
(Ehrenberg et al. 2004). Pedersen’s hypothesis states that fetal macrosomia is a 
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result of fetal hyperinsulinemia secondary to maternal and fetal hyperglycemia 
(Pedersen 1977c). This was confirmed by Susa et al. (1984) in a Rhesus monkey 
model. Continuous fetal insulin infusion without fetal hyperglycemia for 1–3 
weeks in midgestation invariably resulted in fetal macrosomia and organomegaly 
(Susa et al. 1984). Fetal growth stimulation results from hyperinsulinemia, leading 
to increased deposition of fat. Insulin also stimulates amino acid uptake and tissue 
protein synthesis. Both clinical and experimental studies have shown that insulin 
is probably the most important fetal growth-promoting hormone (Hill 1982). Knip 
et al. (1983) showed that macrosomic infants of Type 1 diabetic women had a 
twofold increase in the concentrations of free insulin in cord blood when 
compared with normal weight infants of Type 1 mothers. Similarly, Schwartz et 
al. (1994) found that total and free insulin concentrations in fetal serum correlate 
positively with fetal macrosomia in diabetic pregnancies. In contrast, macrosomic 
fetuses of non-diabetic mothers are not hyperinsulinemic (Schwartz et al. 1994), 
which indicates that  factors other than fetal hyperinsulinemia can also cause fetal 
overgrowth. Fetal hyperinsulinemia can also be endogenic, e.g. in the Beckwith-
Wiedemann syndrome and nesidioblastosis of the fetal pancreas. In both of these 
syndromes the fetuses are typically macrosomic with visceromegaly and they may 
become severely hypoglycemic after birth (DeBaun et al. 2000, Best et al. 2006, 
Chen 2007).  
 
Placental transfer of insulin complexed with antibodies has been suggested as a 
possible reason for fetal macrosomia (Knip et al. 1983, Menon et al. 1990). On the 
other hand, Schwartz et al. (1994) showed that women with Type 1 diabetes who 
do not have insulin antibodies have a similar rate of macrosomic infants compared 
with women who have insulin antibodies. Therefore, the importance of insulin 
antibodies in relation to fetal macrosomia remains uncertain. 
 
Although fetal macrosomia is a result of maternal hyperglycemia, elevated levels 
of amino acids and lipids in the maternal circulation are also associated with fetal 
overgrowth (Hendrickse et al. 1985, Kliegmann and  Gross 1985, Kalkhoff 1991). 
Fibroblast growth factor-2 (FGF-2) may also contribute to overgrowth in fetuses 
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of women with GDM (Hill et al. 1998). Insulin-like growth factor-1 (IGF-1) 
enhances placental amino acid transport (Karl 1995).  
 
Maternal risk factors of  fetal macrosomia    
Both maternal obesity (Kirchengast et al. 1998, Shapiro et al. 2000, Ehrenberg et 
al. 2004, Yogev et al. 2005, Griffiths et al. 2007) and marked weight gain during 
pregnancy (Johnson et al. 1992, Kirchengast et al. 1998, Shapiro et al. 2000, 
DeVader et al. 2007) are important risk factors of fetal macrosomia. In a study of 
women with normal OGTT results, by Jensen et al. (2003a), the risk of 
macrosomia was significantly increased when the BMI was over 25 kg/m2 
compared with those with BMI under 25 kg/m2. Women with a considerable 
weight gain during pregnancy have a 2- to 3-fold increased risk of delivering a 
large-for-gestational age (LGA) infant (Hedderson et al. 2006, DeVader et al. 
2007). The risks of adverse maternal and fetal outcomes are lowest when maternal 
weight gain is optimal (Cedergren 2007). Low maternal gestational weight gain in 
obese women (less than 6 kg for women with a BMI of 30 kg/m2 or more) has 
been shown to decrease the incidences of both maternal and fetal complications 
(Cedergren 2007). 
Ethnicity has an effect on the occurrence of fetal macrosomia, both in the general 
population and in GDM pregnancies (Dornhorst et al. 1996, Rosenberg et al. 
2003, Silva et al. 2006). Caucasian, Japanese and Chinese women have a lower 
risk of fetal macrosomia than native Hawaiin/Pacific-Islander and Filipino 
mothers (Silva et al. 2006). On the other hand, GDM has a greater influence on 
the birth-weight of Asian versus white European offspring (Dornhorst et al. 1996). 
 
 
Although glycemic control among women with Type 1 diabetes has improved in 
recent decades, the rate of fetal macrosomia has not decreased (Persson and 
Hansson 1998, Teramo 1998). Large infants are associated with increased 
perinatal morbidity and mortality. Recently there has been a significant increase in 
mean birth-weight in both European (Surkan et al. 2004) and North American 
populations (Catalano 2007), possibly due to the world-wide obesity epidemic.  
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3.2.3 Intrauterine growth restriction
Intrauterine growth restriction (IUGR) is defined as a relative birth-weight below 
-2 SD of the mean birth-weight. An IUGR infant has, by definition, not reached 
his/her genetic growth potential in utero (Bamberg and Kalache 2004).  Maternal 
pregestational diabetes mellitus may also be associated with IUGR, especially 
when retinopathy and nephropathy complicate diabetes (Reece et al. 1998). In 
patients with retinopathy and nephropathy, vascular adaptation of the placental 
bed is often insufficient, resulting in IUGR. In women with diabetic nephropathy, 
IUGR is observed in 15–21% of cases (Kitzmiller et al. 1981, Reece et al. 1998) 
compared with 3–10% in the normal population (Haram and Gjelland 2007).  
 
Erythropoietin (EPO) is an endogenous hormone which controls the production of 
erythrocytes. The main stimulus to EPO production is low tissue oxygen 
concentration (hypoxia) (Marsden 2006). Teramo et al. (2004) reported that levels 
of amniotic fluid EPO correlate in a U-shaped fashion with fetal birth-weight z-
scores in Type 1 diabetic pregnancies. Amniotic fluid EPO levels correlated 
inversely with the birth-weight z-score below -0.6 SD units, suggesting that these 
fetuses were actually growth restricted and that it was associated with chronic 
fetal hypoxia (Teramo et al. 2004).
3.3 Shoulder dystocia 
3.3.1 General population 
 
Shoulder dystocia can be defined as arrest of delivery after expulsion of the fetal 
head, although no general agreement has been reached (Gottlieb and Galan 2007). 
The incidence of shoulder dystocia varies widely, from 0.1 to 2.8% in unselected 
populations (Acker et al. 1985, Langer et al. 1991, Christoffersson and Rydhström 
2002, Dandolu et al. 2005). Dandolu et al. (2005) reported  that there was an 
increase in the rate of shoulder dystocia from 0.2% in 1979 to 2.1% in 2003. Both 
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excessive maternal weight before pregnancy and weight gain during pregnancy 
are associated with shoulder dystocia (Spellacy et al. 1985, Johnson et al. 1992). 
The incidence of shoulder dystocia is 3–13% in newborn infants with a birth 
weight of 4000 g or more (Benedetti and Gabbe 1978, Acker et al. 1985, Gross et 
al. 1987, Langer et al. 1991). In the study by Acker et al. (1985) the incidence of 
shoulder dystocia was 13% when the birth weight exceeded 4000 g, but only 1% 
when the birth weight was under 4000 g. In California, the percentages of births 
complicated by shoulder dystocia but not complicated by diabetes have been 
reported to be 5.2% for infants weighing 4000 to 4250 g, 9.1% for those weighing 
4250 to 4500 g, 14.3% for those weighing 4500 to 4750 g and 21.1% for those 
weighing 4750 to 5000 g at birth (Nesbitt et al. 1998). Shoulder dystocia has been 
reported to occur in 40% of cases (31/78) when the birth-weight of vaginally 
delivered infants was at least 5700 g (Rydhström and Ingemarsson 1989).  
3.3.2 Diabetic pregnancies 
 
Large fetal size among women with GDM is a common risk factor for shoulder 
dystocia (Bennett 1999). Dystocia occurs more often in GDM pregnancies than in 
non-diabetic pregnancies, even when the birth weights are the same because of 
increased shoulder width. Any type of diabetes mellitus increases the risk of 
shoulder dystocia in vaginal deliveries (Acker 1985, Langer et al. 1991). Dandolu 
et al. (2005) observed an increased rate of shoulder dystocia both in GDM 
pregnancies (OR 1.9, 95% CI 1.7–2.3) and in  pregnancies of women with 
pregestational diabetes (OR 3.8 95% CI 2.7–5.4). The risk of shoulder dystocia 
and trauma is further increased by the use of vacuum or forceps. In  a study by 
Nesbitt et al. (1998) the risk of shoulder dystocia in cases of instrumentally 
assisted births among diabetic women was 12.2% for infants weighing 4000 to 
4250 g, 16.7% for those weighing 4250 to 4500 g, 27.3% for those weighing 4500 
to 4750 g and 34.8% for those weighing 4750 to 5000 g. 
 34
Insulin treatment in cases of GDM has been reported to decrease the rates of  
macrosomia (Roversi et al. 1980, Coustan and Imarah 1984, Langer 1993, Langer 
et al. 1994) and serious perinatal complications such as shoulder dystocia, bone 
fractures and brachial plexus nerve injury (Crowther et al. 2005). Langer et al. 
(2005b) reported a 2- to 4-fold increase in neonatal morbidity in cases of 
untreated GDM. They found an increased rate of macrosomia in the untreated 
GDM group. On the other hand, non-diabetic subjects and diet-treated or diet- and 
insulin-treated GDM patients had the same rate of macrosomia. In another study, 
Langer et al. (2005c) reported that an adverse pregnancy outcome was found in all 
women with GDM who had poor glucose control. On the other hand, obese 
women with GDM (BMI at least 30 kg/m2) had pregnancy outcomes comparable 
with those among  women with GDM and BMI <25 kg/m2 when treated by means 
of diet and insulin but not by diet alone. They had a 2- to 3-fold risk of adverse 
outcome, despite acceptable glucose control with diet therapy. The outcome may 
thus be adverse even when glucose control is considered good. In a study among 
women with Type 1 diabetes, Evers et al. (2002b) showed that the incidence of 
fetal macrosomia was increased despite apparently good glycemic control 
throughout pregnancy.
 
Gestational diabetes mellitus has an unfavorable effect on fetal body composition 
(Neggers et al. 1995, Catalano et al. 2003). Newborn infants of women with GDM 
have increased fat mass compared with the infants of healthy women (Catalano et 
al. 2003). Fat deposition in the human fetus occurs mainly in the third trimester 
(Widdowson et al. 1972). Macrosomic infants of women with Type 1 diabetes 
(Pedersen 1977b) or GDM (Persson and Hanson 1998) also have organomegaly, 
e.g. enlargement of the liver and heart. The growth of these infants may be 
asymmetric, with larger shoulder/head and chest/head ratios than in the infants of 
non-diabetic women (Modanlou et al. 1982, Ballard et al. 1993).  
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3.4 Birth trauma 
 
Shoulder dystocia and high birth-weight are the strongest risk factors as regards 
clavicular and other fractures and brachial plexus injury (Erb’s palsy) (Levine et 
al. 1984, Mollberg et al. 2005). The incidence of brachial plexus injury is 0.15-
0.3%  (Gilbert et al. 1999, Mollberg et al. 2005, Backe et al. 2008). In an analysis 
of  66 086 births, Gregory et al. (1998) reported a brachial plexus injury rate of 
0.1% among vaginally delivered infants weighing under 4000 g, but 0.9% when 
the birth weight was at least 4000 g. Similarly, others have reported rates of 0.6–
1.1%  for brachial plexus injury in vaginally-born infants weighing at least 4000 g 
among mothers without diabetes (Ecker et al. 1997, Kolderup et al. 1997, Bryant 
et al. 1998). The frequency of plexus injury was increased in the infants of women 
with GDM (OR 1.9, 95% CI 1.7–2.1) and in cases of vacuum extraction (OR 2.7, 
95% CI 2.4–3.1) or forceps delivery (OR 3.4, 95% CI 2.7–4.3) (Gilbert et al. 
1999).  Diabetes increases the risk of brachial plexus injury by 2 to 5 times in 
infants weighing at least 4000 g at birth. In a Swedish study the overall perinatal 
mortality rate resulting from shoulder dystocia was 1.2%. It increased to 6.4% in 
mothers with diabetes mellitus (Christoffersson and Rydhström 2002). 
 
Fracture of the clavicle occurs particularly during a difficult vaginal delivery, and 
especially when shoulder dystocia is present, or when the arms are extended in 
breech delivery. Fractures of the humerus (greenstick or full-thickness fracture) at 
birth are seen mostly when the newborn infant is macrosomic or is delivered 
vaginally in breech presentation (Caviglia et al. 2005). Fracture of the skull bones 
is associated with instrumental vaginal delivery (vacuum or forceps) and it may 
result in intracranial hemorrhage (Doumouchtsis and Arulkumaran 2008). 
 
 
3.5 Fetal hypoxia 
 
The incidence of abnormal fetal heart rate pattern during delivery, cord blood 
acidosis and low Apgar scores at birth is increased in diabetic pregnancies, 
indicating an increased risk of fetal hypoxia (Teramo et al. 1983, Mimouni et al. 
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1988, Salvesen et al. 1993, Casson et al. 1997). The exact mechanisms of fetal 
hypoxia are not fully understood. It is likely that several factors, alone or in 
combination, can result in decreased oxygen delivery to the fetus in diabetic 
pregnancies (Madsen 1986). Experimental and human studies have shown that 
both fetal hyperglycemia and hyperinsulinemia can independently cause fetal 
hypoxemia (Carson et al. 1980, Philipps et al. 1982, Milley et al. 1984, Widness et 
al. 1990). Elevated plasma and amniotic fluid EPO levels suggest that the fetuses 
of diabetic women can suffer from chronic hypoxia (Teramo et al. 1987, 2004). 
The iron stores in the fetal liver and brain are totally depleted in most cases of 
stillbirth in diabetic pregnancies reflecting increased erythropoiesis, further 
suggesting that these fetuses die from chronic hypoxia (Georgieff et al. 1992, 
Petry et al. 1992). Concentrations of maternal HbA1c during the last weeks of 
pregnancy correlate directly with fetal cord plasma (Widness et al. 1990) and 
amniotic fluid EPO levels (Teramo et al. 2004), indicating that poor glycemic 
control during the last weeks of pregnancy increases the risk of intrauterine 
hypoxia.  In a recent study of Type 1 diabetic pregnancies, the correlation between 
amniotic fluid EPO concentrations and birth-weight z-scores was U-shaped. 
Below a z-score of -0.6 SD units the correlation was negative but above +1.0 SD 
unit it was positive (Teramo et al. 2004). This suggests that the optimal birth-
weight in Type 1 diabetic pregnancies is relatively narrow, and that fetal chronic 




3.6 Perinatal mortality 
 
Perinatal mortality is in Finland defined according  to WHO as a fetal death 
occurring at or after 22 weeks of gestation and/or 500 g birth-weight or a 
neonatal death occurring during the first 7 days of life. Perinatal mortality has 
decreased from 20–30% to under 5%  during the last 50 years in pregnancies 
complicated by Type 1 diabetes mellitus (Schwartz and Teramo 2000, Gabbe and 
Graves 2003). However, it is still 3–5 times higher, even in centers specializing in 
the care of diabetic pregnancies, than the perinatal mortality rate in the general 
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population (Gabbe et al. 1977, Coustan et al. 1980, Jovanovic et al. 1981, Jensen 
et al. 2004, Macintosh et al. 2006, Bell et al. 2008). In Type 1 diabetic 
pregnancies the perinatal mortality rate ranges from 2.8 to 4.8% (Casson et al. 
1997, Hawthorne et al. 1997, Platt et al. 2002, Penney et al. 2003, Evers et al. 
2004). In a Danish nationwide prospective multicenter study the perinatal 
mortality was 3.1%, which was 4.1-fold higher than that in  the background 
population (Jensen et al. 2004).    
About 30 to 40% of perinatal deaths in Type 1 diabetic pregnancies are caused by 
malformations, and 20 to 30% by prematurity and intrauterine asphyxia, 
respectively (Schwartz and Teramo 2000). Stillbirths after 30 weeks of gestation 
form the majority of perinatal deaths in Type 1 diabetic pregnancies (Schwartz 
and Teramo 2000). Before 30 weeks, prematurity is the main cause of perinatal 
death (Teramo et al. 2005). In the 1950s, the risk of fetal death in Type 1 diabetic 
pregnancies was 5% at 32 weeks of gestation, increasing gradually to 15% at term 
(Hagbard 1956). Chronic fetal hypoxia is postulated to be the most likely reason 
for the majority of  ‘unexplained’ stillbirths in diabetic pregnancies after 35 weeks 
of gestation (Schwartz and Teramo 2000).  
 
There were 1365 consecutive childbirths from 1988 to 2006 at Helsinki 
University Central Hospital among women with pregestational diabetes, of which 
96% had type 1 diabetes (Teramo et al. unpublished data 2007). Perinatal 
mortality was 1.9% (18 stillbirths and 8 neonatal deaths) during the study period 
(Table 1). The decrease in perinatal mortality is partially explained by the 
improved diagnosis of fetal malformations by sonography over the last 20 years. 
There were 12 induced abortions because of severe fetal malformations in women 
with pregestational diabetes during 1988–2006 at  Helsinki University Central 
Hospital, of which at least 10 would have resulted in perinatal death. Thus, the 





Table 1.  Perinatal deaths in Type 1 diabetic pregnancies at the Department of Obstetrics 
and Gynecology, University Central Hospital, Helsinki, during 1988-2006
White’s Perinatal
class   g  z-score death
1      B 23 + 5    575 .. F PROM
2      C 25 + 1    370 - 5.0 F Multiple malformations
3      C 25 + 1    500 - 4.4 N RDS
4      B 25 + 2    725 - 2.8 N RDS
5      B 26 + 0    440 - 4.5 F Preeclampsia
6      D 26 + 1   650 - 2.8 F IVF, twin B
7      C 26 + 3    830 - 1.5 F Unexplained
8      F 26 + 4    785 - 2.1 N RDS
9      C 27 + 6    400 - 5.3 F Placental abruption
10      D 28 + 4    705 - 3.8 N RDS
11      D 29 + 2    1195 - 1.3 F Placental infarctions
12      F 30 + 1    810 - 3.9 N RDS
13      F 30 + 1    1900 +1.7 N Multiple malformations
14      B 31 + 1    1380 - 1.6 F Cord complication
15      D 31 + 2    1255 - 2.4 F Placental abruption
16      C 31 + 5    2160 +1.3 F Maternal ketoacidosis
17      B 33 + 6    1350 - 3.4 F Placental infarctions
18      B 34 + 4    2310 - 0.9 F Unexplained, twin B
19      D 35 + 4    4100 +3.4 N Severe shoulder dystocia
20      C 36 + 0    4030 +2.9 F Unexplained
21      B 36 + 1    2250 - 1.8 F Placental abruption
22      R 36 + 3    4630 +4.5 F Unexplained
23      C 36 + 6    2290 - 0.5 F Unexplained
24      B 37 + 3    6500 +7.8 F Unexplained
25      D 38 + 1    3415 +0.2 F Unexplained
26      D 39 + 2    5000 +3.0 N Heart malformation
F = fetal; N = neonatal; PROM = premature rupture of membranes; 
RDS = respiratory distress syndrome; IVF = in vitro fertilization










Neonatal hypoglycemia is defined as a plasma glucose level below 2.6 mmol/l in 
a full-term infant (Cornblath et al. 2000). The prevalence of neonatal 
hypoglycemia ranges between 0.5 and 4% in infants born at term (Uvena-
Celebrezze and Catalano 2000, Shand et al. 2008). Among  the infants of women 
with GDM, hypoglycemia occurs in 6–19% (Langer et al. 2005, Shand et al. 
2008) and in the pregnancies of pregestational diabetes (Type 1 or Type 2) the 
figure is 25–48% (Cordero et al. 1998, Evers et al. 2004, Shand et al. 2008). High 
amniotic fluid EPO levels obtained within 2 days before delivery can identify 
fetuses with an increased risk of neonatal hypoglycemia in Type 1 diabetic 
pregnancies (Teramo et al 2004). Neonatal hypoglycemia during the first days of 
life is a consequence of fetal hyperinsulinemia (Pedersen 1977b). A decreased 
ability to use glycogen and diminished hepatic glucose production in the first days 
of life predisposes newborn infants to hypoglycemia (Merlob and Hod 2008). 
Impaired counter-regulation by catecholamines may also have a role in the 
development of neonatal hypoglycemia (Schwartz and Teramo 2000). Most 
infants with neonatal hypoglycemia recover spontaneously, but symptomatic and 
prolonged hypoglycemia may result in permanent neurologic impairment or death 
(Armentrout and Caple 1999, Vannucci and Vannucci 2001). 
 
 
 4.2 Respiratory distress syndrome 
 
The risk of respiratory distress syndrome (RDS) in newborn infants  of Type 1 
diabetic mothers is increased compared with that in the general population when 
matched for gestational age (Robert et al. 1976). Poor glycemic control during the 
last week of pregnancy has been shown to delay fetal lung maturation (Ylinen 
1987), whereas the risk of RDS in infants of women with diabetes in good 
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glycemic control approaches that in the non-diabetic population (Kjos et al. 1990). 
Evaluation of fetal lung maturity by means of analysis of amniotic fluid has been 
recommended in insulin-treated diabetic pregnancies when an elective cesarean 
section is contemplated before the 38th gestational week (Hallman and Teramo 
1979).   
 
 
4.3 Polycythemia  
 
Fetal polycythemia is defined as cord blood hematocrit at or above 65% at birth. 
The occurrence of polycythemia is increased in infants of diabetic mothers 
(Salvesen et al. 1992). These infants have polycythemia up to five times more 
often than infants of non-diabetic women (Mimouni et al. 1986). Fetal 
polycythemia is a result of accelerated erythropoietin-induced red blood cell 
production in response to chronic fetal hypoxia (Shannon et al. 1986, Widness et 
al. 1990, Teramo and Widness 2008). Polycythemia may lead to hyperviscosity 





The definition of neonatal hyperbilirubinemia is complicated. Both gestational age 
and the age of the newborn infant are related to serum bilirubin levels. A serum 
bilirubin concentration exceeding 205–222 μmol/l in term infants is considered 
abnormally high (Maisels 1992). Hyperbilirubinemia complicates up to 20% of 
the newborn infants of women with GDM compared with 10% in the general 
population (Uvena-Celebrezze and Catalano 2000). Hyperbilirubinemia has been 
reported in 24 to 45% of the newborn infants of Type 1 diabetic pregnancies 
(Teramo et al. 1979, Cordero et al. 1998).  The etiology of the increased 
frequency of hyperbilirubinemia in diabetic pregnancies is not fully understood. It 
may be due to delayed clearance of bilirubin in newborn infants of diabetic 
mothers (Stevenson et al. 1987). In addition, polycythemia contributes to 
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hyperbilirubinemia because of the increased  amount of breakdown products 
(Merlob and Hod 2008). 
 
 
4.5 Hypocalcemia and hypomagnesemia
 
Hypocalcemia and hypomagnesemia in infants of diabetic mothers are clinically 
less important than other neonatal complications. Maternal magnesium and 
parathyroid hormone concentrations are decreased in diabetic women, which may 
result in fetal hypomagnesemia (Uvena-Celebrezze and Catalano 2000) and this in 
turn can lead to reduced concentrations of fetal parathyroid hormone and 
hypocalcemia. Neonatal hypocalcemia is defined as an ionized serum calcium 
level below 1.05 mmol/l and hypomagnesemia as a plasma magnesium level of 
less than 0.5 mmol/l. Hypocalcemia affects 18–32% of infants born to Type 1 
diabetic women (Teramo et al. 1979, Demarini et al. 1994). The severity of 
hypocalcemia has been reported to correlate with the degree of glycemic control 
during pregnancy (Tsang et al. 1975, Demarini et al. 1994). 
 
 
4.6 Obstructive cardiomyopathy 
 
Fetuses of women with pregestational diabetes have an increased risk of 
developing cardiac septal hypertrophy (Walther et al. 1985, Vela-Huerta et al. 
2000). This may be due to fetal chronic hypoxia as indicated by elevated amniotic 
fluid EPO levels (Teramo and Widness 2008). Newborn infants with obstructive 
cardiomyopathy often have cyanosis or cardiac failure during the first days of life 
(Gutgesell and Speer 1980). On the other hand, infants with cardiomyopathy may 
remain asymptomatic during the newborn period, and regression to normal tends 
to occur by 3–6 months of age (Merlob and Hod 2008). 
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AIMS OF THE STUDY 
 
                                             
The present study was undertaken to investigate maternal and fetal outcomes in 
pregnancies complicated by gestational or Type 1 diabetes mellitus.  
 
The specific aims of the study were: 
 
1.  to clarify the relationship between glucose control and pregnancy-induced  
hypertension and preeclampsia in women with GDM 
 
2. to study the ability of the 2-hour oral glucose tolerance test combined with the 
24-hour glucose profile to distinguish between low and high risks of  fetal  
macrosomia in GDM pregnancies 
 
3. to assess the effect of glucose control on the risk of fetal malformations in   
women with Type 1 diabetes  
 
4.  to study the risk of pregnancy-induced hypertension  and preeclampsia in       
relation to glucose  control in women with Type 1 diabetes  
 43
SUBJECTS AND METHODS 
Subjects
 
A total of 986 women with GDM and 203 women with borderline glucose 
intolerance (one abnormal value in the OGTT) with a singleton pregnancy, 488 
pregnant women with Type 1 diabetes (691 pregnancies and 709 offspring), and 
1154 pregnant non-diabetic women (1181 pregnancies and 1187 offspring) at 
Helsinki University Central Hospital were investigated. The study protocols were 
approved by the local ethics committee (Studies I–IV) and the Ministry for Social 
Affairs and Health  (Studies II–IV).
Study I 
All 284 consecutive women with gestational glucose intolerance and  singleton 
childbirth (81 women with GDM and 203 women with borderline glucose 
intolerance) between April 1, 1987 and March 31, 1988 at Helsinki University 
Central Hospital were prospectively studied  for   pregnancy complications and 
perinatal outcome. Control subjects consisted of  327 healthy women with normal 
OGTT results at 28–32 weeks of gestation and with singleton childbirth at the 
same hospital during the same time period. These control subjects were 
population-based and participated in another study in which all pregnant women 
underwent OGTTs.
Study II 
This study included 520 diet-treated and 385 insulin- and diet-treated women with 
GDM  and singleton childbirth  at Helsinki University Central Hospital during 
1988–1997. These two GDM cohorts were studied retrospectively to assess the 
effects of hyperglycemia and other factors on fetal macrosomia and birth trauma. 
If a  woman had two or more childbirths during the study years, only the last 
pregnancy was included in the study. The control group consisted of 805 non-
diabetic women residing in the town of Kerava (near Helsinki),  who participated 
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in routine ultrasosonography screening at 16–19 weeks of gestation and who had a 
singleton childbirth during 1993–95.  
Study III 
In order to assess the relationship between glycemic control in early pregnancy 
and the risk of congenital malformations, 691 consecutive pregnancies in 488 
women with Type 1 diabetes and their 709 offspring were studied between 1988 
and 1997 at Helsinki University Central Hospital. Control subjects consisted of 
735 newborn infants from 729 consecutive pregnancies of 709 non-diabetic 
women from the town of Kerava, who attended routine ultrasonographic 
screening at 16–19 weeks of gestation, with  childbirth at Helsinki University 
Central Hospital in 1993–1995.  
Study IV 
From the same study and control subjects as in the malformation study (Study III), 
683 Type 1 diabetic pregnancies in 480 women and 854 pregnancies in 827 
control women with childbirth at Helsinki University Central Hospital (residents 
of Kerava) were followed throughout pregnancy in order to evaluate the possible 





1. Screening, diagnosis and treatment of gestational diabetes mellitus 
 
The data of the women and their newborns were collected from patient records. In 
the catchment area of Helsinki University Central Hospital, all pregnant women 
with at least one risk factor for GDM (Table 2) underwent a 2-hour oral glucose 
tolerance test (OGTT). The test was normally performed at 24–28 weeks of 
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pregnancy, and earlier when indicated. About 30% of Finnish pregnant women 
have at least one of risk factor for GDM (Hyvönen 1991).  
 
 
Table 2.  The 2-hour oral glucose tolerance test (OGTT) with 75 g of glucose was 
done in patients with one or more of the following risk factors
Family history of diabetes
GDM in previous pregnancy
Prepregnancy BMI >25 kg/m2
Age >40 years 
Glucosuria in current pregnancy 
Birth-weight >2 SD-units or >4500 g in previous pregnancy
Suspicion of fetal macrosomia in current pregnancy
Previous infant with hypoglycemia or major malformation





The 2-hour OGTT was carried out with 75 g of glucose after a 12-hour overnight 
fasting. Samples for plasma glucose measurements were obtained immediately 
before (fasting value) and at 1 and 2 hours after the 75 g glucose load. The results 
were considered abnormal if any of the three plasma glucose values equalled or 
exceeded the 97.7th percentile value derived from a Finnish control population 
(Hyvönen 1991). The 97.7th percentile values were 5.1 mmol/l at 0 hour, 10.0 
mmol/l at 1 hour and 8.7 mmol/l at 2 hours. In the present study the diagnosis of 
GDM was made when 2 or 3 values of the 2-hour OGTT were abnormal. Patients 




Women with an abnormal OGTT result received dietary counseling aiming at 
normoglycemia. Within one week, women with two or three abnormal values had 
a 24-hour glucose profile carried out in the hospital with samples taken at 4-hour 
intervals, i.e. a total of 7 plasma glucose measurements. The measurements were 
done at 8.00, 12.00, 16.00, 20.00, 24.00, 04.00, and 08.00 o’clock. The 
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measurements  at 12.00 and 20.00 o’clock were postprandial. In Study I, women 
with one abnormal glucose value in the OGTT also underwent a 24-hour glucose 
profile. Insulin treatment was started with a single dose of 8–16 units of NPH 
insulin daily, usually in the evening in addition to the diet, when two fasting 
values were at least 5.5 mmol/l, or one fasting value was at least 5.5 and one 
postprandial value at least 7.8 mmol/l. Women with GDM and on insulin 
treatment measured their blood glucose at home 5 times a day, 2 to 3 days a week. 
Insulin-treated GDM patients were followed at the outpatient maternity clinic at 
2- to 4-week intervals. Women with only one abnormal OGTT value were 
followed at the maternity health care centers. Their fasting plasma glucose levels 
were measured at 2- to 4-week intervals. As long as the fasting plasma glucose 
level remained under 5.5 mmol/l, diet therapy was considered sufficient. When 
diet alone failed to achieve normoglycemia, the 24-hour glucose profile was done 
as described above.   
 
 
2. Follow-up and treatment of Type 1 diabetic pregnancies 
Pre-pregnancy planning and care was recommended to all women with 
pregestational diabetes. However, only 40% of the Type 1 diabetic women were 
seen in the outpatient maternity clinic of this hospital. Of the remaining 60%, 
many had been counseled by their family doctor or a diabetologist, but their exact 
number is not known.  
 
 
Women with Type 1 diabetes attended the outpatient maternity clinic of this 
hospital at  2-to 6-week intervals during the first two trimesters and more 
frequently during the third trimester. They were advised to measure their blood 
glucose concentration at home as described above for women with insulin-treated 
GDM. A long acting NPH insulin preparation was administered once or twice 
daily. In addition, a short-acting insulin preparation was used at meals, in most 
patients three or four times a day. Consultation with a dietician was arranged in 
early pregnancy and later when needed. Retinal examination was carried out done 
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by an ophthalmologist in early pregnancy if the last evaluation of the retina had 
preceded the pregnancy by more than 6 months. The first ultrasonography was 
performed in early pregnancy and after that carried out every 4–8 weeks. For 
detection of major fetal malformations a comprehensive  ultrasonographic 
examination was performed by a perinatologist at 16–20 weeks of gestation. 
Monitoring by cardiotocography was carried out  at each visit after 28 weeks of 
gestation and after 34 weeks also between visits as needed. The patients routinely 
underwent amniocentesis for evaluation of fetal lung maturity, at the latest at 37 
completed weeks of pregnancy or earlier if complications appeared. In diabetic 
pregnancies, the fetal lungs were considered functionally mature when the 
lecithin/sphingomyelin ratio was >2 and phosphatidylglycerol was detected in the 
amniotic fluid (Hallman and Teramo 1979, Hallman et al 1980). Labor was 
induced or elective cesarean section performed when fetal lung maturity was 
demonstrated in the amniotic fluid. Elective cesarean section was preferred in 
patients of White’s classes D, R or F. Indications for cesarean section delivery 
were fetal macrosomia or signs of fetal distress. 
 
 
3. Blood pressure measurement and evaluation of proteinuria  
Blood pressure was measured after 10-15 minutes’ rest with the subject in a 
sitting or semi-recumbent position with a mercury sphygmomanometer. The 
diastolic blood pressure level was obtained from the Korotkoff phase V 
(disappearance of sounds). The measurements were carried out as part of the 
routine clinical follow-up by midwives and nurses. Blood pressure during 
pregnancy was considered increased if the following two criteria were met at two 
sessions at least 24 h apart: (1) diastolic pressure increased by 15 mmHg or more 
from the first measurement during pregnancy until the end of pregnancy, and (2) 
the final level reached 90 mmHg or more. In the analyses, the second highest 
blood pressure value was used.
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Urine was checked for protein by a semi-quantitative dipstick method at each 
clinical visit. Results of  ‘++’ or repeated ‘+’ were confirmed by way of a 
quantitative analysis. A diagnosis of proteinuria was made if the amount of 
protein excretion was  0.3 g  or more/24 h. 
 
Chronic hypertension was defined as diastolic blood pressure of more than 90 
mmHg repeatedly in the first trimester. Pregnancy-induced hypertension was 
defined as diastolic blood pressure of 90 mmHg or more repeatedly after 20 
weeks of gestation in previously nonhypertensive women. Preeclampsia was 
defined as PIH with proteinuria of 0.3 g/24 h or more (Study IV). In Study I both 
preeclampsia and PIH were defined as diastolic blood pressure of more than 90 
mmHg repeatedly after 20 weeks of gestation.  
 
 
4. Plasma glucose measurement 
 
In Study I plasma glucose was determined using a photometric hexokinase 
method (Kone Specific, Espoo, Finland). In Studies II–IV plasma glucose was 
measured by means of  a glucose oxidase electrode with amperometric detection 
(ESAT 6660®, Eppendorf, Hamburg, Germany).     
5. Assessment of long-term glycemic control  
Concentrations of glycated hemoglobin were assessed (as HbA1c) by means of an 
HPLC method (Diamat®, Bio-Rad Laboratories, Hercules, California, USA) at the 
first visit of Type 1 diabetic women to the maternity outpatient clinic and 
thereafter every 4 to 6 weeks until delivery. Using this method, the mean HbA1c 
value  is 4.93% (SD 0.32) in healthy non-diabetic Finnish adults. Values less than 
5.6% (mean + 2 SD) were considered normal. 
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In Study IV three values of HbA1c were selected as follows: the first measurement 
in the first trimester, the second at 22 weeks of gestation and the third the last 
measurement before delivery. The first HbA1c assessment was carried out at 7 
weeks of gestation (median) and in 93% of the women by the end of the 14th 
week. For the mid-pregnancy measurement, the value obtained closest to 22 
weeks was used (range 20–25 weeks). The last measurement before delivery was 
obtained at 2 weeks before delivery (median, range 0–4 weeks).  
 
 
6. Assessment of the health of the newborn infant 
 
After delivery, the infants of diabetic mothers were observed for at least two hours 
at the labor and delivery ward. Newborn infants were transferred to the neonatal 
intensive care unit in cases of respiratory distress, neonatal hypoglycemia, or 
difficulties in adaptation after delivery. Blood glucose was measured four times 
during the first day of life and later as indicated in infants of Type 1 and GDM 
pregnancies. Neonatal hypoglycemia was defined as a blood glucose 
concentration below 1.8 mmol/l at least twice and at least one of these after six 
hours of age (Study I). Neonatal hyperbilirubinemia was considered present when 
bluelight phototherapy or exchange transfusions were indicated. Relative birth-
weight (standardized for gestational age and fetal sex)  was expressed as standard 
deviation units (z-scores) using a large Finnish standard population as reference 
(Pihkala et al 1989). The newborn infant was considered macrosomic if the birth-
weight was more than 2.0 SD-units (97.7th percentile). The frequency of infants 
with a  birth-weight over the 90th percentile was also calculated in GDM 
pregnancies for comparison (Study II). Infants of women with diabetes and 
control subjects were examined by a neonatologist after birth and at 2–5 days of 
age at discharge from the hospital. A malformation was classified as ‘major’ if it 
was fatal, likely to cause a serious handicap, or if it required surgery. Other 
malformations were classified as ‘minor’, which included undescended testis, 
hydrocele of the scrotum and dislocation of the hip. Each offspring was classified 
according to the most serious disorder as having either major, minor, or no 
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For continuous variables, Student’s t-test and the Mann-Whitney U-test were used 
to compare two groups. For more than two groups, comparisons were carried out 
by way of one-way ANOVA and the Bonferroni procedure, or by way of the 
Kruskal-Wallis test. Categorial data and proportions were compared either with 
the Chi-square test (with Yates’ correction as needed), or by calculating the rate 
difference and its 95% CI. Trends in proportions were evaluated by the Armitage 
test. Fisher’s exact probability test was used for small numbers when appropriate. 
Relative risks or odds ratios with 95% CIs were calculated for different risk 
factors. Multiple logistic regression was used to identify variables independently 
associated with the outcome. All tests were two-sided. Values of p less than 0.05 
were considered statistically significant. Calculations were performed using Arcus 
Quickstat Biomedical (Longman Software Publishing, Cambridge, UK) and the 
NCSS 2000 software (NCSS Inc., Kaysville, Utah, USA). 
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RESULTS
1. Pregnancy-induced hypertension, preeclampsia and gestational diabetes 
mellitus (Study I) 
1.1 Maternal  clinical data 
 
Women with GDM and with two or three abnormal values in the OGTT (GDM 
group) were older than the control women and their pre-pregnancy BMIs were 
higher than the BMIs of the controls (Table 3). Women with one abnormal value 
in the OGTT (borderline group) also had higher BMIs than the controls. However, 
weight gain during pregnancy was lowest in the women with GDM (Table 3).  




Table 3. Maternal data (mean and SD or frequency) of women with gestational diabetes 
(GDM), of women with one abnormal value in the OGTT (borderline glucose intolerance),   
and of non-diabetic healthy pregnant women (controls) (Study I)
                Controls
                                       Borderline GDM
Number of women 327 203 81
Maternal age (years)           31.2  (4.6) 32.2    (5.2) 33.2    (5.5)a
Pre-pregnancy weight (kg)       59.3  (8.8) 62.8  (12.6)a 68.0  (14.5)b
Body mass index (kg/m2)     21.8  (2.9) 23.4    (4.3)b 25.5    (5.1)b
Pregnancy weight gain (kg) 14.0  (3.7) 13.3    (5.2) 10.6    (5.3)b
Cesarean sections (%) 53   (16.2) 44     (21.7) 25     (30.9)a   




1.2 Frequency of hypertensive pregnancy complications
 
 
The frequency of hypertensive pregnancy complications was higher in the GDM 
patients (two or three abnormal values in the OGTT) than in the non-diabetic 
controls (19.8% vs. 6.1%, p<0.001). The frequency of chronic hypertension was 
also higher in the GDM women than in the controls (2.5% vs. 0.3%, p<0.05). 
Women with borderline glucose intolerance (one abnormal value in the OGTT) 
had the same frequency of hypertensive complications as the controls.  
 
 
2. Fetal macrosomia and gestational diabetes mellitus (Study II) 
2.1 Maternal characteristics   
 
Of the 905 GDM women, 520 (57.5%) were treated by means of diet only and 
385 (42.5%) by means of diet and insulin. Both the diet- and diet plus insulin-
treated GDM patients were older and more obese and had previously given birth 
more often to a newborn infant weighing >4000 g than the non-diabetic controls 
(Table 4). The insulin-treated GDM women had more childbirths than the 
controls, whereas the diet-treated women had the same mean parity as the 
controls. The cesarean section rate was more than twice as high in the insulin-






Number of women 805 520 385
Nulliparous (%) <0.001b
Age (years) 29.5  (5.0) 33.5  (5.4) 34.0  (5.4) <0.001a
Body mass index (kg/m2) 23.1  (3.9) 26.1  (5.4) 29.0  (6.8) <0.001a
Cesarean section (%) <0.001a
Previous child's 
 birth-weight >4000 g (%)   72   (8.9) <0.001a
insulin
332 (41.2) 187 (36.0) 91   (23.6)
Table 4.  Maternal characteristics of women with GDM and of healthy controls. Values 
are means (SD) or frequencies (Study II)
GDM, diet only GDM, diet + 
aBoth GDM groups differ from controls
bInsulin-treated GDM group differs from controls and diet-treated GDM group
150 (18.6) 140 (26.9) 163 (42.3)







Fetal macrosomia occurred more often in the insulin-treated GDM pregnancies 
(18.2%, p<0.001) than in the diet-treated GDM pregnancies (4.4%) or the controls 
(2.2%) (Table 5). However, the number of newborn infants with a birth-weight 
over the 90th percentile was significantly higher in the diet-treated GDM 
pregnancies than in the controls (Table 5). The rate of Erb’s palsy in vaginally 
delivered infants was 2.7% in the insulin-treated group and 2.4% in the diet-







Table 5.   Clinical data of the newborn infants of women with GDM and of healthy controls. 
Values are means (SD) or frequencies (%) (Study II)
Controls p
insulin
Number of newborn infants 805 520 385
Gestational age (days)   278   (13)   277    (11)   265   (11) <0.001b
Birth-weight (g) 3517 (570) 3616  (580) 3624 (677) <0.001a
Birth-weight z-score
    >2 SD-units (>97.7th percentile)     18  (2.2)     23   (4.4)     70 (18.2) <0.001b
Birth-weight >90th percentile     70  (8.7)     77 (14.8)   143 (37.1) <0.001a
Erb's palsy in vaginal deliveries (%)       2  (0.3)       9   (2.4)      6   (2.7)   <0.001a
aBoth GDM groups differ from controls      
bInsulin-treated GDM group differs from controls and diet-treated GDM group





2.3 Fetal macrosomia and pre-pregnancy BMI
The proportion of macrosomic newborn infants was highest in insulin-treated 
GDM patients even when the maternal BMI was under 25 kg/m2 (Figure 1). 
However, the prevalence of fetal macrosomia was more than twice as high (24.7% 
vs. 11.9%) in obese (BMI at least 30 kg/m2) than in non-obese (BMI <25 kg/m2) 
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Figure 1.  Frequency of macrosomia as a function of pre-pregnancy BMI in non-
diabetic controls (grey columns) and in diet-treated (checkered columns) and 
insulin-treated (black columns) women with GDM. The numbers above the 




2.4 Fetal macrosomia and the 2-hour oral glucose tolerance test  
 
 
When the women with GDM were grouped according to their 2-hour plasma 
glucose values in the OGTT, the frequency of macrosomia was significantly 
higher in all groups than in the controls, even when the 2-hour value was below 
7.8 mmol/l (Figure 2). In contrast, the fasting value in the 2-hour OGTT of the 







Figure 2. Distribution of 66 macrosomic newborn infants of 782 women with 
GDM as a function of the 2-hour plasma glucose level in the OGTT (black 
columns). The frequency of macrosomia in the controls is also shown for 
comparison (grey column).  There was no significant trend among the GDM 
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Controls 3.5-4.7 4.8-5.2 5.3-5.5 5.6-5.9 ≥6.0



















Figure 3. Distribution of 66 macrosomic newborn infants of 782 women with 
GDM as a function of the fasting plasma glucose level in the 2-hour OGTT (black 
columns). The frequency of macrosomia in the non-diabetic controls is also 
shown for comparison (grey column). The trend among the GDM patients was 
highly significant (p<0.001). The numbers above the columns indicate the 
numbers of macrosomic newborn infants. 
 
 
3. Congenital malformations in pregnancies with Type 1 diabetes (Study III) 
 
 
3.1 Frequency and type of fetal malformations  
 
 
A major fetal malformation was observed in 30 (4.2%) of the 709 offspring in 
Type 1 diabetic women and in 10 (1.4%) of the 735 control offspring (RR 3.1; 
95% CI 1.6–6.2). The corresponding frequencies of minor malformations were 
6.1% among Type 1 diabetic pregnancies and 3.0% among the controls. The 
combined frequencies of major and minor malformations were 10.3% in diabetic 
pregnancies and 4.4% in the controls. 
Fasting plasma glucose level (mmol/l) in the OGTT 
 58
Cardiovascular malformations (12/30) were the most common type of major 
malformation in the diabetic pregnancies. Musculo-skeletal (6/30), central 
nervous system (4/30) and gastrointestinal malformations (4/30) were also 
common among the major malformations. Induced abortion because of a major 
fetal malformation was carried out in five of the Type 1 diabetic and in none of 
the control pregnancies.  
 
 
3.2 Glycemic control and fetal malformations
 
The relative risk of major malformation was 3.0 (95% CI 1.2–7.5) when 
comparing Type 1 diabetic women with non-diabetic controls, even in those 
diabetic women whose HbA1c level was only slightly increased (by 2.0 to 5.9 SD-
units) (Table 6). Only diabetic women with normal HbA1c  levels (less than 5.6%) 
had the same low risk as the control subjects. The mean maternal HbA1c level was 
6.4% in those infants with a central nervous system malformation and 7.6% in 





Table 6. Hemoglobin A1c in early pregnancy in women with Type 1 
diabetes and the risk of major fetal malformations compared with 
non-diabetic control subjects (Study III)
First trimester HbA1c Relative risk
   (%) SD-units (95% CI)
<5.6        <2.0 1/47
5.6-6.8 2.0-5.9 7/170 3.0 (1.2-7.5) 
6.9-8.0 6.0-9.9 8/252 2.3 (1.0-5.7)
8.1-9.3 10.0-13.9 6/133 3.3 (1.3-8.6)
>9.4 >14.0 4/61 4.8 (1.6-13.9)
Unknown      Unknown 4/49 6.0 (2.0-17.1)
Offspring of diabetic women 30/709 3.1 (1.6-6.2)






4. Hypertension and glycemic control in Type 1 diabetic pregnancies (Study IV)  
4.1 Glycemic control 
Preeclampsia was diagnosed in 12.8% of the women with Type 1 diabetes 
(excluding those with pre-pregnancy nephropathy) and in 2.7% of the control 
women (OR 5.2; 95% CI 3.3–8.4). A positive correlation was observed between 
the HbA1c level in early pregnancy and the occurrence of preeclampsia (Table 7). 
Pregnancy-induced hypertension was observed in 11.4% of the diabetic women 
(excluding those with pre-pregnancy nephropathy), compared with 5.6% of the 
control women (OR 2.2, 95% CI 1.5–3.1). Unlike preeclampsia, no association 








Table 7.  Frequency of preeclampsia and PIH in Type 1 diabetic women without 
diabetic nephropathy grouped according to HbA1c level and in control subjects
(Study IV)
HbA1c
in early pregnancy Number % %
<5.6%     41 2   4.9 4 9.8
5.6-6.8%                 154 11   7.1 14 9.1
6.9-8.0%                  221 30 13.6 31 14.0
>8.0%                            171 34 19.8 16 9.4
Unknown 29 2    6.9 5 17.2
Non-diabetic controls 854 23    2.7 48 5.6
a Armitage test for trend p<0.001
Number




4.2 Risk factors of preeclampsia
 
Glycemic control, nulliparity, diabetic retinopathy and duration of diabetes were 
statistically significant independent predictors of preeclampsia calculated by 
multiple logistic regression analysis (Table 8). The adjusted odds ratios for 
preeclampsia were 1.6 (95% CI 1.3–2.0) for each 1% unit increment in the HbA1c 
value during the first trimester and 0.6 (95% CI 0.5–0.8) for each 1% unit 
decrement achieved during the first half of pregnancy. Changes in glycemic 
control during the second half of pregnancy did not alter the risk of preeclampsia. 
Of the 67 patients with pre-pregnancy nephropathy, 38 (57%) had preeclampsia or 




Table 8. Factors associated with preeclampsia in 616 Type 1 diabetic women without
diabetic nephropathy (Study IV)
                             
 OR 95% CI OR 95% CI    p
Nulliparity  2.9 1.9-4.5 2.7 1.7-4.3     <0.0001 
Retinopathy  3.0 2.0-4.5 2.0 1.2-3.3   0.0001
Duration of diabetes 1.3a 1.2-1.5 1.2a 1.0-1.5   0.02
HbA1c in early pregnancy 1.3b 1.1-1.5 1.6b 1.3-2.0 <0.0001 
HbA1c improvement until mid- 1.0c 0.9-1.2 0.6c 0.5-0.8 <0.0001 
   pregnancy
a Increase of risk for each additional 5 years duration of diabetes
b Increase of risk for each 1% unit increment of HbA1c
c Reduction of risk for each 1% unit decrement of HbA1c
Unadjusted Adjusted
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DISCUSSION     
1. Gestational diabetes mellitus 
 
1.1 Screening and diagnosis
The main purpose of screening for GDM is to find the women with a high risk of 
maternal and perinatal complications. The prevalence of GDM has been 
increasing  in recent decades (Ferrara et al. 2004, Dabelea et al. 2005). Therefore, 
it is a growing challenge to detect pregnancies at risk of GDM as early as possible 
during pregnancy. The best strategy would be to prevent the occurrence of GDM, 
but no controlled studies on GDM prevention have  been published so far.
 
The diagnosis of GDM is based on the results of a glucose tolerance test carried 
out  either with a 75 or 100 g glucose load. The 75 g OGTT is carried out as a 2-
hour test whereas the 100 g OGTT is  a 3-hour test (Metzger and Coustan 1998). 
The cut-off levels as regards  abnormal values differ considerably in different 
countries and they have also been changing during the last 30 years. The cut-off 
plasma glucose values of the 2-hour OGTT recommended by the 4th Workshop-
Conference on GDM and the American Diabetes Association  are 5.3, 10.0 and 
8.6 mmol/l for the fasting, 1-hour and 2-hour values, respectively (Metzger and 
Coustan 1998, American Diabetes Association 2004). These cut-off values have 
recently been adopted as the new recommendations for GDM screening and 
diagnosis in Finland (The Finnish Working Group on Gestational Diabetes 2008). 
In the present study the cut-off plasma glucose values used for the diagnosis of 
GDM were based on the results of a large population-based Finnish study 
(Hyvönen 1991). These values differ only slightly from those recommended by 
the 4th Workshop-Conference on GDM (Metzger and Coustan 1998). 
The fact that no consensus has been reached on how to screen for GDM suggests 
that no single screening method has been considered superior. Recently, it has 
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been suggested that almost all pregnant women should be screened for GDM 
(Kaaja and Rönnemaa 2008). Only women considered to have a very low risk do 
not need to be screened. However, the possible benefits of the universal screening 
for GDM have so far not been sufficiently studied. By way of the screening 
method used in the present study, combined with a 24-hour glucose profile, we 
could separate  GDM pregnancies at high and low risks of fetal macrosomia. 
Those who needed insulin therapy had a high risk of fetal macrosomia. To our 
knowledge no other method for detection of high risk GDM pregnancies has been 
as efficient as the present study.     
 
The results of previous studies (Nord et al. 1995, Jensen et al. 2003b, Berg et al. 
2007) and those of the present study (II) show that the degree of the severity of 
GDM, as indicated by high blood glucose values and the need of insulin 
treatment, clearly influences the complication rates. The results of a recent large 
multicenter study indicated that no clear cut-off levels exist for any of the 2-hour 
OGTT plasma glucose values above which perinatal complications are markedly 
increased (Metzger et al. HAPO 2008). Therefore, the cut-off values of plasma 
glucose levels in the diagnosis of GDM are arbitrary. No general agreement has 
been reached in defining the diagnostic cut-off levels for GDM.  
 
1.2 Preeclampsia and pregnancy-induced hypertension 
 
Preeclampsia and PIH occurred significantly more frequently in the women with 
GDM than in the controls (Study I), which is in agreement with most other studies 
(Nordlander et al. 1989, Persson and Hanson 1998, Starcevic and Djelmis 2004, 
Östlund et al. 2004, Hunger-Dathe et al. 2005). In women with GDM the rate of 
preeclampsia is 2.0 to 3.3 times greater than in non-diabetic controls. In the 
present work (Study I) the rate of preeclampsia and PIH in GDM women was 3.2 
times higher than in the healthy controls. Furthermore, the incidence of obesity 
was higher in the patients with GDM than in the healthy controls, which also 
contributed to the increased risk of preeclampsia and PIH. At least one group of 
investigators has found no increase in pregnancy-induced hypertensive disorders 
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in GDM pregnancies (Schaffir et al. 1995). Although an increased risk of 
preeclampsia has been reported in women with mild glucose intolerance (only one 
abnormal value in the OGTT) (Lindsay et al.1989), our work (Study I) did not 
show  such an association. In a study by Ros et al. (1998) GDM was associated  




Fetal macrosomia is one of the main complications of GDM pregnancies and it 
can result in both maternal and perinatal birth trauma, perinatal hypoxia and even 
fetal death. The definition of macrosomia used in the present work (Studies I and 
II; birth-weight z-score > +2.0 SD-units) is relatively strict. In many studies fetal 
macrosomia is defined as a birth- weight >90th percentile of a reference 
population. The +2.0 SD above the mean corresponds to the 97.7th percentile in a 
normally distributed cohort. Fetal macrosomia occurred in 18.2% of insulin-
treated GDM pregnancies when > +2.0 SD was used as the definition of 
macrosomia. When the >90th percentile (> +1.28 SD) definition was used in the 
same pregnancies, 37.1% of the newborn infants were macrosomic.   
 
In the present work (Study II) the fasting plasma glucose value of the 2-hour 
OGTT correlated well with fetal macrosomia, which is in agreement with the 
results of other studies (Lindsay et al. 1989, Sermer et al. 1995, Fadl et al. 2006, 
Metzger et al. HAPO 2008). In contrast, the 2-hour value of the OGTT in the 
present study did not correlate with fetal macrosomia, which differs from the 
finding in the HAPO study (Metzger et al. HAPO 2008). The explanation for this 
difference could be that the number of subjects in the present study was too small, 
or that the difference could be due to ethnic (genetic) differences in the 
populations studied. 
 
In our series the 2-hour value of the OGTT alone, as proposed by the WHO 
(Alberti and Zimmet 1998), could not be used to separate GDM pregnancies with 
an increased risk of fetal macrosomia from those with a low risk. Fetal 
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macrosomia occurred as frequently in GDM women with a 2-hour glucose value 
below 7.8 mmol/l as in GDM women with a 2-hour value above 9.0 mmol/l 
(Study II). 
 
It has been reported that insulin treatment in addition to diet results in lower rates 
of macrosomia compared with diet treatment alone in GDM pregnancies (Coustan 
and Imarah 1984, Langer et al. 2005b). In a randomized study, women with 
GDM, with diet and insulin treatment as needed, had lower rates of macrosomia 
and other perinatal complications compared with women with GDM having 
routine care without GDM treatment (Crowther et al. 2005). It is therefore 
important to achieve normoglycemia by means of  adequate treatment in all GDM 
pregnancies. 
 
The high frequency of macrosomic fetuses in insulin-treated GDM pregnancies in 
the present study suggests that the treatment of GDM was insufficient or it was 
started too late. It is also possible that what was considered good glycemic control 
was not good enough to prevent fetal macrosomia. One of the main aims of future 
research is to develop methods that would identify in early pregnancy, or even 
before pregnancy, those women who will develop GDM, especially those with an 
increased risk of having a macrosomic fetus.  
 
 
 1.4 Neonatal brachial plexus injury 
 
The incidence of shoulder dystocia and Erb’s palsy are increased among the 
newborn infants of GDM pregnancies (Gilbert et al. 1999, Mollberg et al. 2005), 
and also among LGA infants of non-diabetic pregnancies (Ecker et al. 1997, 
Kolderup et al. 1997, Bryant et al. 1998). Shoulder dystocia was not recorded in 
the present work (Studies I and II) because of the difficulty of defining it. In the 
present study Erb’s palsy occurred in vaginal deliveries at the same high 
frequency in both diet- and insulin-treated GDM pregnancies (Study II). Although 
the absolute birth-weights in the diet-treated GDM and control pregnancies 
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differed only slightly, Erb’s palsy occurred more than five times more often in the 
diet-treated GDM group than in the controls. The most likely explanation for this 
difference is the unfavorable effect of GDM on fetal body composition (Neggers 
et al. 1995, Catalano et al. 2003). Newborn infants of mothers with GDM have 
large shoulder/head and chest/head ratios compared with the newborn infants of 
healthy women (Modanlou et al. 1982, Ballard et al. 1993). It is noteworthy that 
13 of the 15 newborn infants with Erb’s palsy among the GDM pregnancies in the 
present work (Study II) weighed more than 4000 g at birth.   
 
It is difficult to identify pregnancies at an increased risk of shoulder dystocia and 
brachial plexus injury. Fetal shoulder width cannot be reliably assessed by 
ultrasongraphy, in contrast to fetal abdominal circumference measurement 
(Landon et al. 1989). However, fetal weight, shoulder width and maternal pelvic 
capacity can be measured by magnetic resonance imaging (MRI) (Baker et al. 
1994, Spörri et al. 1997, Tukeva et al. 2001). Therefore, MRI should be used more 
frequently for fetal shoulder width and body volume (weight) measurements, 
especially in diabetic pregnancies and when fetal macrosomia is suspected. It is 
important that every obstetrical unit has guidelines how to manage shoulder 
dystocia in order to prevent brachial plexus injury. 
 
In the present study insulin-treated GDM patients had a significantly higher 
cesarean section rate than the diet-treated GDM patients (Study II). This may be 
one of the reasons why Erb’s palsy was not more frequent in the insulin-treated 
GDM pregnancies than in the diet-treated pregnancies, although fetal macrosomia 
occurred four times more frequently in the insulin-treated pregnancies than in the 
diet-treated GDM pregnancies. It is also possible that the diagnosis of diet-treated 
GDM could have given a false sense of safe vaginal delivery compared with the 
insulin-treated GDM women, although the diagnosis of GDM seems to favor the 
decision to deliver by cesarean section (Sermer et al. 1995, 1998).   
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2. Type 1 diabetes mellitus 
 
2.1 Glycemic control during pregnancy    
In the present study, glycemic control in Type 1 diabetic pregnancies was mainly 
based on home monitoring of plasma glucose values and repeated HbA1c 
measurements in the outpatient maternity clinic, which is in line with international 
recommendations (Gabbe and Graves 2003, Jovanovic and Kitzmiller 2008).  
2.2 Fetal malformations 
 
The majority of clinical studies on Type 1 diabetic pregnancies indicate that poor 
glycemic control immediately before conception or during the first trimester is 
associated with an increased risk of fetal malformations (Miller et al. 1981, 
Fuhrmann et al. 1983, Ylinen et al. 1984, Rose et al. 1988, Greene et al. 1989, 
Steel et al. 1990, McElvy et al. 2000, Evers et al. 2004, Inkster et al. 2006, 
Nielsen et al. 2006). These results support the concept that maternal 
hyperglycemia is responsible for the increased risk of fetal malformations. It was 
previously thought that fetal malformations occur only when the maternal mean 
glucose level is above a certain threshold level (Greene et al. 1989, Hanson et al. 
1990). However, the results of the present work (Study III) suggest that an 
increased risk of fetal malformations occurs even when HbA1c levels are only 
slightly increased in early pregnancy. In fact, only women with normal HbA1c 
levels in early pregnancy showed the same low fetal malformation rate as the non-
diabetic control women. This is the first study in which the results suggest that 
there is no increased glucose threshold above which an increased risk of fetal 
malformations occurs.  
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The exact pathogenic mechanism by which hyperglycemia causes fetal 
malformations in diabetic pregnancies is not known. Most likely several 
mechanisms exist.  Experimental studies suggest that oxidative stress may have an 
important role in the teratogenicity of diabetic pregnancies (Cederberg and 
Eriksson 2005). The observation that the central nervous system malformations in 
our series were associated with relatively low HbA1c values suggests that factors 
other than maternal hyperglycemia could also be involved in the pathogenesis of 
some fetal malformations in diabetic pregnancies. Folic acid supplementation is 
included in the recommendations for the care of Type 1 diabetic pregnancies (Ray 
et al. 2001). 
 
At our hospital, the rate of major malformations in the newborn infants of women 
with Type 1 diabetes decreased from 7.7% in 1978–1982 (Ylinen et al. 1984) to 
4.4% in 1988–1997 (Study III). During the same time period, the mean level of 
HbA1c of the first measurement in early pregnancy decreased from 8.2% to 7.7%, 
which at least partly explains the reduction in the rate of fetal malformations. The 
most likely cause for the improved glycemic control was the introduction of home 
monitoring of glucose levels in the 1980s. Pre-pregnancy counceling and 
centralization of the care of Type 1 diabetic pregnancies may also have resulted in 
the improved glycemic control. 
 
2.3 Preeclampsia and pregnancy-induced hypertension 
2.3.1 Risk factors 
 
The increased risk of preeclampsia in Type 1 diabetic pregnancies (White 1949, 
Pedersen  et al. 1974, Hanson and Persson 1998, Sibai et al. 2000) was also 
observed in the present work (Study IV). The most important risk factor of 
preeclampsia in women with Type 1 diabetes is nephropathy (White 1949, 
Pedersen 1977). On the other hand, it is difficult to define superimposed 
preeclampsia in women with diabetic nephropathy (Hanson and Persson 1998).  
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In addition to the duration of diabetes and nulliparity, we found that diabetic 
retinopathy and poor glycemic control were significant independent risk factors of 
preeclampsia. The observations are in accordance with those in previous reports 
(Funai et al. 2005, Howarth et al. 2007, Luo et al. 2007). Furthermore, it has been 
reported that the frequency of preeclampsia increases with increasing severity of 
diabetic complications (Sibai et al. 2000). However, in a recent study no 
relationship between the risk of preeclampsia and the duration of diabetes was 
observed (Howarth et al. 2007).   
 
In the present work the risk of PIH among women with Type 1 diabetes without 
nephropathy was twice that of non-diabetic controls (Study IV). Garner et al. 
(1990) and Siddiqi et al. (1991) have also reported an increased risk of PIH in 
women with Type 1 diabetes. Unlike preeclampsia, PIH was not associated with 
poor glycemic control during pregnancy in the present study, which was also an 
observation noted in a Swedish study (Hanson and Persson 1998). In a follow-up 
study carried out by Gordin et al. (2007)  it was suggested that preeclampsia, but 
not PIH, increased the risk of diabetic nephropathy later in life. These 
observations suggest that preeclampsia and PIH are two different entities with 
different pathogenetic mechanisms, at least in pregnancies complicated by Type 1 
diabetes.   
2.3.2 Glycemic control
 
The association between poor glycemic control in early pregnancy and  the 
occurrence of preeclampsia in women with Type 1 diabetes observed in Study IV 
has been reported previously (Combs et al. 1993, Rosenn et al. 1993, Hsu et al. 
1996, 1998, Hanson and Persson 1998). The results of the present study indicate 
that glycemic control during the first half of pregnancy influences the occurrence 
of preeclampsia in the second half of pregnancy. Each 1% unit increment in the 
level of HbA1c during the first trimester of pregnancy corresponded to a 1.6-fold 
increase in the risk of preeclampsia. 
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 It has been suggested that improvement of glycemic control during pregnancy 
reduces the risk of preeclampsia (Hsu et al. 1996). The results of the present study 
are in accordance with this. After adjusting for confounding factors, each 1% unit 
decrement in the HbA1c level achieved by mid-pregnancy reduced the risk of 
preeclampsia by a factor of 0.6. However, a change in HbA1c values during the 
latter half of pregnancy did not influence the occurrence of preeclampsia. This is a 
further example of the importance of maintaining and improving glycemic control 
throughout pregnancy in order to decrease both maternal and perinatal 
complications in diabetic pregnancies.  
 
 
The mechanism is not clear, why good glycemic control in early pregnancy exerts 
a beneficial effect during the latter half of pregnancy on the incidence of 
preeclampsia. One could speculate that a possible reason could be the so called 
‘metabolic memory’ phenomenon, which was observed in studies examinating the 
long term effects of good glycemic control on diabetic complications (DCCT 







1. Women with gestational diabetes mellitus have an increased risk of 




2. The fasting plasma glucose value in the 2-hour OGTT is a better predictor of 
fetal macrosomia than the 2-hour value. A 24-hour glucose profile carried out 
within a week after the diagnosis of GDM distinguishes between pregnancies with 
a low risk (diet-treated) and a high risk (insulin-treated) of fetal macrosomia. 
 
3. No threshold level of mean maternal plasma glucose concentrations exists, 
above which fetal malformations are likely to occur. Even a slightly increased 
HbA1c level during early pregnancy in women with Type 1 diabetes mellitus 
carries an increased risk of fetal malformations. 
 
4. In women with Type 1 diabetes, poor glycemic control during the first trimester 
of pregnancy is associated with an increased risk of preeclampsia but not 
pregnancy-induced hypertension. Improvement of glycemic control by mid-
pregnancy reduces the risk of preeclampsia. 
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